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BACKGROUND: A cointervention in a randomized clinical trial (RCT) is medical care given in addition to the tested intervention. 
If cointerventions are unbalanced between trial arms, the results may be biased. We hypothesized that cointerventions would 
be more adequately reported in RCTs without full blinding or at risk of bias.
METHODS AND RESULTS: To describe the reporting of cointerventions and to evaluate the factors associated with their reporting, 
we did a systematic search of all RCTs evaluating pharmacological interventions on cardiovascular outcomes published in 5 
high- impact journals. The reporting of cointerventions, blinding, and risk of bias were extracted and evaluated independently 
by 2 reviewers (E.M., L.A.). Cointerventions were inadequately reported in 87 of 123 RCTs (70.7%), with 56 (45.5%) providing 
no information on cointerventions and 31 (25.2%) providing only partial information. Of the RCTs, 52 (42.3%) had inadequate 
blinding of participants and/or personnel and 63 (51.2%) of the RCTs were judged at risk of bias. In univariable analysis, the 
reporting of cointerventions was not associated with blinding of participants and/or personnel (odds ratio [OR], 1.04; 95% CI, 
0.47–2.27 for adequately versus inadequately blinded trials) or with risk of bias (OR, 1.47; 95% CI, 0.67–3.21 for at low risk 
of bias versus trials at risk of bias). In multivariable analysis, only a follow- up of <1 month was associated with the adequate 
reporting of cointerventions (OR, 3.63; 95% CI, 1.21–10.91).
CONCLUSIONS: More than two- thirds of recent major cardiovascular trials did not adequately report cointerventions. The quality 
of reporting was not better among trials that were not fully blinded or at risk for bias.
REGISTRATION: URL: https://www.crd.york.ac.uk/PROSP ERO/. Unique identifier: CRD42018106771. 
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Because randomized clinical trial (RCT) outcomes shape clinical guidelines and daily practice,1,2 we expect them to meet the highest standards 
of methodological quality and provide us with robust 
results.3,4  RCTs have benefitted from continuous im-
provement in methodological quality,5 especially in 
random sequence generation and allocation conceal-
ment, which have freed them from baseline confound-
ing.5–7 However, randomization does not eliminate 
differences that may arise between treatment groups 
during follow- up. After randomization, bias can arise 
when participants receive medical care in addition to 
the intervention of interest (cointerventions)6,8 if it is not 
provided equally to all treatment groups.8–11 
When one group receives more cointerventions than 
another, the RCT results may be compromised by bias.6–
8,11 This unequal distribution of cointerventions might be 
caused by a failure to adequately blind participants and/
or personnel.12–14 For example, if investigators know that 
a participant is receiving an active substance in a trial 
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designed to prevent myocardial infarction (eg, new an-
tidiabetic drugs), they might suggest that the participant 
take other medications that reduce cardiovascular risk 
(eg, statins). If a family doctor knows that a patient is 
not receiving the active substance, he or she might feel 
ethically bound to prescribe effective cointerventions.8 If 
cointerventions affect one group more than another, the 
results could be biased in either direction.6,8 To reduce 
the risk of bias, cointerventions should be reported in 
both unblinded (ie, open label) and in double- blind trials 
because blinding can be compromised during the course 
of even a double- blind RCT by, for example, drugs that 
are not adequately matched, specific side effects, or lab-
oratory investigations (such as lipid measurements).15–19 
It is difficult to measure unblinding in a double- blind 
RCT, but we can and should quantify its possible conse-
quences by reporting relevant cointerventions.13,16,17
Patients in cardiovascular trials often receive multiple 
treatments (eg, statins, antihypertensives, antiplatelets) 
beyond the studied medication, each of which could af-
fect outcomes, so cointerventions and in particular these 
comedications may play an important role in cardiovas-
cular RCTs, especially if unblinded.6,8,20,21 After several 
years without new potent drugs for cardiovascular pre-
vention, a number of large RCTs have demonstrated the 
benefit of recent drugs for cardiovascular prevention,22–27 
but in some there was risk that cointerventions were un-
balanced between study groups. We designed this sys-
tematic review to evaluate the quality of cointervention 
reporting in recently published RCTs with cardiovascular 
outcomes and to evaluate potential explanatory factors 
for reporting. We hypothesized that cointerventions would 
be more adequately reported in RCTs that were not fully 
blinded or otherwise at risk of bias because unbalanced 
cointerventions between trial arms may be more likely in 
these studies and could compromise their findings.
METHODS
Selection of Articles
We searched MEDLINE and EMBASE for RCTs evaluat-
ing pharmacological interventions on binary cardiovascu-
lar outcomes (fatal and/or nonfatal myocardial infarction, 
fatal and/or nonfatal stroke, mortality as well as compos-
ite outcomes) published in the 5 general medical journals 
with the highest impact factors (New England Journal 
of Medicine, Lancet, Journal of the American Medical 
Association, British Medical Journal, and Annals of 
Internal Medicine) between 2011 and 2019 (see Table S1 
for details of the search strategy). Our methods conform 
to the Preferred Reporting Items for Systematic Reviews 
and Meta- Analyses (PRISMA) statement for reporting 
systematic reviews and meta- analyses.28 The protocol is 
registered on PROSPERO (CRD42018106771). One re-
viewer (E.M.) screened all titles and abstracts, assessed 
the full text of eligible abstracts and articles, and identified 
relevant trials. Another investigator (L.A.) independently 
assessed the eligible abstracts. The data that support the 
findings of this study are available from the corresponding 
author upon request. 
Assessment of Included RCTs
The following information was extracted: study design 
(superiority versus noninferiority/equivalence trials), 
number of patients, type of intervention and compara-
tor, follow- up duration, outcomes, information concern-
ing methods of blinding of participants and personnel, 
blinding of outcome assessors, information about coin-
terventions, implementation of study treatment, adher-
ence to study treatment, cross- overs, statistical analysis 
conducted, and funding source (industry versus nonin-
dustry). Available information on cointerventions, blind-
ing of participants and/or personnel, adherence to 
study treatment, and statistical analysis was extracted 
CLINICAL PERSPECTIVE
What Is New?
• In this systematic review of major cardiovascu-
lar trials in 5 highly influential medical journals, 
cointerventions were inadequately reported in 
more than two-thirds of the trials, whereas the 
quality of reporting was not better among trials 
that were not fully blinded or at risk for bias.
What Are the Clinical Implications?
• Cointerventions should be systematically re-
ported in cardiovascular trials to assess the va-
lidity of the findings, particularly when trials are 
not fully blinded.
Nonstandard Abbreviations and Acronyms
OR odds ratio
RCT randomized clinical trial
RR relative risk 
CONSORT  Consolidated Standards of 
Reporting Trials
INR International normalized ratio
PRISMA  Preferred Reporting Items for 
Systematic Reviews and 
Meta-Analyses
SPORTIF  Stroke Prevention Using the Oral 
Direct Thrombin Inhibitor Ximelagatran 
in Patients With Atrial Fibrillation
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independently by 2 reviewers (E.M., L.A.). All available 
information was extracted from the original trial reports, 
supplementary material, and protocols (if available).
Definition of Cointerventions and Quality 
of Their Reporting
Two investigators (E.M., L.A.) independently assessed 
the cointervention reporting. Because we included RCTs 
with cardiovascular outcomes, we considered potential 
cointerventions whose modification has been shown to 
decrease cardiovascular risk (Box 1).8,29–34 We defined 
cointerventions as concomitant medications (statins, 
antihypertensives, antiplatelets) over follow- up (Box 1). 
In addition, diuretics, antidiabetics, and anticoagulants 
were also included in the definition of “cointervention” 
if these patients were included in the trials (ie, patients 
with heart failure, diabetics, or atrial fibrillation). We also 
defined 2 special categories of cointerventions in (1) 
RCTs where there was an index procedure after ran-
domization, in which case, in addition to concomitant 
medications (statins, antihypertensives, antiplatelets) 
over follow- up, procedural characteristics and peripro-
cedural medications between the groups would also be 
cointerventions29,30,33 (Box S1), and (2) in RCTs with an 
index procedure after randomization but with a follow-
 up of <1 month in which case cointerventions would be 
procedural characteristics and periprocedural medi-
cations without considering concomitant medications 
(statins, antihypertensives, antiplatelets; Box S1).29,30,33 
Although advice for smoking, diet, and physical activ-
ity are also effective cointerventions, they are difficult to 
quantify, are rarely assessed in the original studies, and 
are therefore not evaluated in the present study.
To evaluate the reporting quality of cointerventions in 
each RCT, cointerventions were judged as adequately re-
ported if the authors reported all cointerventions across 
trial arms (as described in Box 1) or if the authors explicitly 
stated that cointerventions did not differ between groups 
or gave indirect evidence that cointerventions did not dif-
fer between groups (eg, “there were no differences be-
tween groups in blood- pressure or cholesterol levels”) or 
that there were no cointerventions. We judged cointerven-
tions as inadequately reported if information in the article 
or supplement was incomplete (ie, partially reported) or 
missing (ie, not reported). Trials that did report cointer-
ventions were classed as either “balanced” if there were 
similar levels of cointerventions between both groups or 
“unbalanced” and were judged by 2 reviewers (E.M., L.A.) 
independently. Disagreements were resolved by consen-
sus in discussions that involved a third author (M.F.).
Assessment of Blinding and the risk of bias
We independently assessed the blinding of partici-
pants and/or personnel. We based our judgments 
about blinding participants and/or personnel on the 
Cochrane Collaboration risk of bias tool 2011 (Risk of 
bias 1.0) and instructions from Unverzagt et al (Table 
S2).35 We classified RCTs into having adequate blind-
ing or inadequate blinding. 
Two authors (E.M., L.A.) used the risk of bias 2.0 
tool to independently assess risk of bias caused by 
deviations from the intended interventions (effect of 
adhering to treatment),13 and classified RCTs as at high 
risk of bias, some concerns, or at low risk of bias. For 
our analysis, we grouped together RCTs judged as 
“some concerns” and RCTs judged as “at high risk of 
bias” and classed them all as “at risk of bias.”
In general, there was good agreement regarding 
the previous classifications: Cohen’s κ score for in-
terobserver variability was 0.84 for the reporting of 
cointerventions, 0.87 for blinding participants and/or 
personnel, and 0.76 for the RoB 2.0 assessment.
Statistical Analysis
We used descriptive statistics. Comparisons be-
tween groups were conducted using a chi- square 
test. We used univariable and multivariable logistic 
regressions to evaluate the association of reporting 
of cointerventions with blinding (adequately versus 
inadequately), risk of bias (trials at low risk of bias ver-
sus trials at risk of bias), funding (nonindustry funded 
versus industry funded), design (superiority versus 
noninferiority/equivalence), and duration of follow- up 
(≤1  month versus >1  month). Finally, in an analysis 
that was not prespecified in the protocol, we looked 
at RCTs that adequately reported cointerventions 
Box 1. Definition of Reporting
The reporting was adequate if all of the following elements were 
reported and inadequate if 1 or more elements were missing.* 
Cointerventions are defined as the following:
• Concomitant medications (statins, antihypertensives, 
antiplatelets) over follow-up.31,32,34†
Special conditions:
• If randomization before an index procedure‡ and follow-up 
>1 month: concomitant medications (statins, antihypertensives, 
antiplatelets†) over follow-up and procedural characteristics and 
periprocedural medications.29,30,33§
• If randomization before an index procedure‡ and follow-up 
<1 month: procedural characteristics and periprocedural 
medications.29,30,33§
*Information could be anywhere in main article or supplements. 
Cointerventions should be summarized by percentages or absolute 
number across groups or the authors should state explicitly in the 
main text that cointerventions did not differ across the groups.† 
Includes others depending on the condition under study, for 
example, antidiabetics in trials that included patients with diabetes 
mellitus or diuretics if heart failure or anticoagulants in trials that 
included patients with atrial fibrillation; see the detailed descriptions 
in Table S3.‡ Index procedures included percutaneous coronary–
angiography (n=18), cardiac surgery (n=5), surgery (n=2), and 
ablation (n=1); see the detailed description in Table S3.§ For more 
detailed descriptions of procedural characteristics/periprocedural 
medications, see Box S1. 
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and explored the aforementioned factors for their 
association with balanced cointerventions between 
treatment arms using univariable logistic regression. 
P values were 2- sided and considered significant if 
P<0.05. For data management, analysis, and graph-
ics, we used Stata version 15.0. 
RESULTS
General Characteristics of Included RCTs
The literature search identified 1625 potentially eli-
gible reports. After screening titles and abstracts, 
we evaluated 149 full articles, of which 123 met the 
inclusion criteria (Figure S1). A detailed description 
of the excluded trials is provided in Table S3. Table 
S4 describes the main characteristics of the 123 in-
cluded RCTs: 83 (67.5%) were published in the New 
England Journal of Medicine; 27 (21.9%) had a nonin-
feriority/equivalence design; 94 (76.4%) were indus-
try funded; 45 (36.6%) examined antithrombotics or 
anticoagulants; 16 (13.0%) involved antidiabetics; 14 
(11.4%) involved antihypertensives; and 17 (13.8%) 
were lipid- modifying agents (Table S4). The primary 
end points of all trials were composite end points 
(Table S5), and all of the trials had blinded adjudica-
tion committees.
Reporting of Cointerventions
As seen in Table, cointerventions were inadequately 
reported in 87 of 123 RCTs (70.7%), with 56 (45.5%) 
providing no information on cointerventions and 31 
(25.2%) providing only partial information (Table). Table 
S5 provides detailed descriptions of the potential coint-
erventions in the protocols, all cointerventions reported 
and not reported, and the time points of reporting in 
each RCT. As seen in Table S6, the results remained 
similar in a stratified analysis based on medication cat-
egory. Assessing potential cointerventions at regular 
intervals, usually at each visit and the last visit, was 
often included in study protocols (Table S5). Protocols 
were not available in only 7 RCTs.
The Reporting of Cointerventions in Relation 
to Quality of Blinding and Risk of Bias
A total of 71 (57.7%) RCTs adequately blinded par-
ticipants and/or personnel, whereas 52 (42.3%) were 
inadequately blinded. Of the RCTs, 60 (48.8%) were 
at “low risk of bias”; 63 (51.2%) were “at risk of bias” 
(n=28, 22.8% as “some concerns”; n=35, 28.5% as “at 
high risk of bias”) because they deviated from planned 
interventions. Among the 52 trials with inadequate 
blinding of participants and/or personnel, 15 (28.9%) 
adequately reported cointerventions versus 21 (29.6%) 
in those with adequate blinding (P=0.93; Figure A). 
Among the 63 trials “at risk of bias,” 16 (25.4%) ad-
equately reported cointerventions versus 20 (33.3%) in 
those “at low risk of bias” (P=0.33; FigureB).
Factors Associated With Adequately 
Reporting Cointerventions
As seen in Table S7, the odds ratio (OR) in the univari-
able analysis for adequately reporting cointerventions 
was 1.04 (95% CI, 0.47–2.27) comparing adequately 
versus inadequately blinded trials, 1.47 (95% CI, 0.67–
3.21) comparing trials “at low risk of bias” versus trials 
“at risk of bias,” 2.06 (95% CI, 0.86–4.92) comparing 
non- industry- funded trials versus industry- funded tri-
als, 0.63 (95% CI, 0.26–1.55) comparing superiority 
trials versus noninferiority/equivalence trials, and 4.33 
(95% CI, 1.63–11.52) comparing trials with a follow- up 
≤1 month versus >1 month (Table S7). In multivariable 
analysis, only a follow- up of <1 month was associated 
with the adequate reporting of cointerventions (OR, 
3.63; 95% CI, 1.21–10.91; Table S7).
Factors Associated With Balanced 
Cointerventions
As seen in Table, among the 36 RCTs that adequately 
reported cointerventions, cointerventions were bal-
anced in 31 and unbalanced in 5 trials. All trials with 
unbalanced cointerventions were judged as inad-
equately blinded trials and were industry funded. As 
seen in Table S8, no other factor was associated with 
unbalanced cointerventions, even though the confi-
dence intervals were large.
DISCUSSION
In this systematic review of recent RCTs on cardio-
vascular outcomes, more than two- thirds of RCTs 
did not adequately report cointerventions. Reporting 
was not better among trials that were not fully blinded 
Table. Reporting of Cointerventions (n=123)
Variable* Sample, n (%)
Adequately reported 36 (29.3)
 Balanced 31/36 (86.1)
 Unbalanced 5/36 (13.9)
Partially reported 31 (25.2)
 Balanced 26/31 (83.9)
 Unbalanced 5/31 (16.1)
Not reported 56 (45.5)
*“Adequately reported” indicates if cointerventions of interest were 
reported across trial arms; “partially reported” indicates if only part of the 
information was provided; “not reported” indicates if there was no reporting 
on potential cointerventions in the published article or the supplements (see 
Box 1).
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nor among RCTs at risk of bias in which the report-
ing of cointerventions would be particularly impor-
tant to assess the validity of their results. Adequate 
reporting of cointerventions was more common in 
trials that followed patients for <1  month, perhaps 
because cointerventions are easier to assess over a 
short follow- up.
Lack of blinding could lead to biased results through 
many different ways. Indeed, an association between 
lack of blinding and positive results has been shown, 
especially when the outcomes were subject to ascer-
tainment bias, that is, not “hard” outcomes.36 RCTs with 
inadequate blinding seem particularly at risk for unbal-
anced cointerventions,14 and reporting cointerventions 
is important because if they are unbalanced between 
treatment arms, they could introduce bias.6,8,11,13 In an 
earlier systematic review of 12 complementary/alterna-
tive medicine RCTs, cointerventions (use of analgesics) 
were reported in 7 of these studies, and it was shown 
that not blinding participants was associated with an 
1.55 increased risk (95% CI, 0.99–2.43) of receiving 
cointerventions.12 The lack of blinding and cointerven-
tions could also explain the differences in the effect 
sizes between SPORTIF III (Stroke Prevention Using 
the Oral Direct Thrombin Inhibitor Ximelagatran in 
Patients With Atrial Fibrillation),21 an open- label trial 
evaluating the effect of ximelagatran versus warfarin 
on strokes and systemic embolic events and SPORTIF 
V,20 a trial with otherwise similar design and end points 
with SPORTIF III, but double-blinded. Although the 
potential risk factors were well balanced across the 
treatment arms within each trial, the effect sizes were 
remarkably different between the 2 trials: SPORTIF III, 
primary event rate 1.6% per year with ximelagatran and 
2.3% per year with warfarin (relative risk [RR], 0.71; 95% 
CI, 0.48–1.07) versus SPORTIF V, primary event rate 
1.6% with ximelagatran per year and 1.2% with war-
farin per year (RR, 1.38; 95% CI, 0.91–2.10).  Outcome 
assessments were blinded in both trials. Indeed, in 
a pooled analysis of the 2 trials,37 it was shown that 
the differences between the trials could be attributed 
to differences in cointerventions such as statins and 
differences in other risk factors (eg, hypertension), in 
addition to less variability in international normalized 
ratio (INR) control in SPORTIF V,37,38 although ascer-
tainment bias cannot be excluded. In our review, the 
reporting of cointerventions was scarce in both RCTs 
with adequate and inadequate blinding, and we found 
no association between blinding and the reporting of 
cointerventions. The reasons for this could be that 
the reporting of cointerventions in cardiovascular tri-
als might have received less attention and/or be less 
standardized. Although the Consolidated Standards 
of Reporting Trials (CONSORT) statement recognizes 
that a lack of blinding may influence the use of coint-
erventions, subsequent reporting of cointerventions 
across groups is currently not mandatory.14 However, 
cointerventions are among the data required to be col-
lected in a Cochrane systematic review.13,39 
In cardiovascular medicine, cointerventions may 
be particularly important because participants usu-
ally receive many different treatments that could re-
duce cardiovascular risk and change cardiovascular 
outcomes.6,8 In the Women’s Health Initiative, which 
Figure. Proportion of trials reporting cointerventions according to blinding and risk of bias.
A, Proportion of trials reporting cointerventions according to blinding of participants and/or personnel (n=123). For the analysis, 
we grouped together the trials with no information on cointerventions and partial information and defined them as “not adequately 
reported”; P=0.93 for the comparison between groups. B, Proportion of trials reporting cointerventions according to risk of bias 
attributed to deviation of intended interventions (n=123). For the analysis, we grouped (1) trials with some concerns and at high risk 
of bias and defined them as “at risk of bias” attributed to the deviation of intended interventions and (2) trials with no information on 
cointerventions and partial information and defined them as “not adequately reported”; P=0.33 for the comparison between groups. 
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examined the effect of hormone therapy on cardiovas-
cular outcomes, the differential use of statins showed 
significantly different effects on coronary heart disease 
and stroke, confounding the results.6 A recently pub-
lished RCT on the effects of coronary computer tomog-
raphy on cardiovascular outcomes, which did not blind 
participants or personnel, found that the participants 
assigned to the intervention group were more likely to 
receive additional preventive treatments for cardiovas-
cular disease (statins, antihypertensives, antiplatelets).40 
In a double- blind RCT designed to test the effects of 
fenofibrate versus placebo on hard cardiovascular end 
points, 17% of the participants on placebo were also 
treated with statins versus 8% in the fenofibrate group, 
which may have caused the results to be biased toward 
the null.10 In many cardiovascular trials, depending on 
the type of intervention, the presence of cointerventions 
may reflect the effectiveness of the study treatment that 
occurs in a real world instead of a perfect hypothetical 
study scenario, and the blinding of participants and/or 
personnel may not always be possible. Nevertheless, 
as cointerventions may lead to an overestimation of 
treatment effect, this is of particular concern when the 
results of an RCT are used for the registration of a new 
drug. In addition, in this systematic review, we included 
RCTs with pharmacological interventions (and not sur-
gery or with devices), so that in these cases blinding is 
usually feasible.
This study has limitations. First, the results were 
limited to cardiovascular trials published in major 
medical journals, which represent a minority of pub-
lished clinical research. However, trials published in 
journals with high impact factors usually do better in 
terms of the quality of reporting,5 and previous meth-
odological reviews have used the same design.41 
Second, this study did not evaluate the reporting of 
cointerventions in medical fields other than cardio-
vascular. Third, the definition of which cointerven-
tions should be reported is (to some extent) arbitrary. 
We proposed a definition (Box  1) that was easy to 
apply, reflected by a high interobserver agreement 
(Cohen’s κ, 0.84).
CONCLUSIONS
More than two- thirds of recent major cardiovascular 
trials did not adequately report cointerventions. The 
quality of reporting was not better among trials that 
were not fully blinded or at risk of bias. Our review high-
lights the need for more standardized, systematic re-
porting of cointerventions in cardiovascular trials.
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Table S1. Literature search. 
(((("Annals of internal medicine"[Journal]) OR ("BMJ (Clinical research ed.)"[Journal]) OR 
("JAMA"[Journal]) OR ("Lancet (London, England)"[Journal]) OR ("The New England journal of 
medicine"[Journal])) AND (randomized controlled trial[pt] OR controlled clinical trial[pt] OR 
randomized[tiab] OR placebo[tiab] OR drug therapy[sh] OR randomly[tiab] OR trial[tiab] OR groups[tiab] 
NOT (animals[mh] NOT humans[mh]))) AND (("Cardiovascular Diseases/drug therapy"[Mesh] OR 
"Cardiovascular Diseases/mortality"[Mesh] OR "Cardiovascular Diseases/prevention and control"[Mesh]) 
OR ("Myocardial Ischemia/drug therapy"[Mesh] OR "Myocardial Ischemia/mortality"[Mesh] OR "Myocardial 
Ischemia/prevention and control"[Mesh]) OR ("Myocardial Infarction/drug therapy"[Mesh] OR "Myocardial 
Infarction/mortality"[Mesh] OR "Myocardial Infarction/prevention and control"[Mesh]) OR ("Stroke/drug 
therapy"[Mesh] OR "Stroke/mortality"[Mesh] OR "Stroke/prevention and control"[Mesh]) OR 
("Cerebrovascular Disorders"[Mesh:noexp]) OR ("Ischemic Attack, Transient"[Mesh]) OR ("Intracranial 
Embolism and Thrombosis"[Mesh]) OR ("Intracranial Arteriosclerosis"[Mesh:noexp]))) NOT 
((comment[Publication Type]) OR (letter[Publication Type])) Filters: Publication date from 2011/01/01 to 
2019/04/11 
*The last update of the search was on 11.04.2019 
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Table S2. Adequate and inadequate blinding of participants and/or personnel. 
 *based on risk of bias due to lack of/insufficient blinding of participants and/or personnel of the Cochrane 
Collaboration risk of bias tool 2011 and on the basis of the instructions used from Unverzagt et al. (see ref. 
35)  
  
                                        Inadequate Adequate 
High Some concerns Low 
Open-label, Single-blind 
The method of masking was 
described and it was 
inappropriate (e.g. comparison of 
tablet versus injection with no 
double dummy) 
 
 
No Information 
The authors stated that the study 
was double-blind but there was no 
adequate description in the text or 
in protocol (e.g. “matching 
placebo”) 
Treatments administered from 
care-givers  (i.v. i.m. injections): 
with no other description 
concerning the preparation (e.g. 
similar colour or matched, opaque 
syringes or bottles) 
Unblinding is possible (e.g. blood 
investigations, specific adverse 
effects) & no methods to avoid 
unblinding 
 
Both patients and caregivers 
were blinded 
Detailed description about how 
the blinding status was 
established and maintained  
(either in published paper of in 
protocol): matching placebo or 
adequate description  
No specific adverse effects or 
methods to avoid unblinding 
included in the protocol 
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Table S3. Description of 26 excluded studies. 
Author, y Reason for exclusion 
Anderson, 2016 (PMID:27161018) Primary outcome: death or disability define 
through modified Rankin scale 
He, 2014 (PMID: 24240777) Primary outcome: death and major disability 
through modified Rankin scale 
Kirchhof, 2012 (PMID: 22713626) Primary outcome: persistent atrial fibrillation or 
death 
Sandercock, 2012 (PMID: 22632908) Primary outcome: proportion of patients alive 
and independent, as defined by an Oxford 
Handicap Score  
Torres, 2014 (PMID: 25399731) Primary outcome: death, end-stage renal 
disease, or a 50% reduction from the baseline 
estimated GFR 
Sabatine, 2015 (PMID: 25773607) Other outcome;CV events assessed as 
prespecified exploratory analysis 
Robinson, 2015 (PMID: 25773378) 
 
Other outcome;CV events assessed as post hoc 
analysis  
Beckett, 2011 (PMID: 22218098) Extension of a randomised, clinical trial 
Bonow, 2011 (PMID: 21463153) Substudy  
De Boer, 2011 (PMID: 22077236) Extension of a randomised, clinical trial 
Gerstein, 2014 (PMID: 25088437) Analysis of data from other randomised, clinical 
trial 
Leonardi, 2016 (PMID: 27677503) Substudy 
Scirica, 2012 (PMID: 22932716) Substudy 
Wang, 2016 (PMID: 27348249) Substudy 
Williamson, 2016 (PMID: 27195814) Substudy/already included 
Zannad, 2015 (PMID: 25765696) Posthoc/already included 
Zoungas, 2014 (PMID: 25234206) Extension of a randomised, clinical trial 
Macdougall, 2013 (PMID: 23343062) Other outcome;CV events assessed only as 
safety 
Newby, 2014 (PMID: 24930728) Other outcome;CV events assessed only as 
safety 
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Cleland, 2011 (PMID: 21856481) 
 
Other outcome;CV events assessed only as 
safety 
Marchioli, 2013 (PMID: 23216616) Combination of pharmaceutical and non 
pharmaceutical treatments 
Ohman, 2017 (PMID: 28325638)  
 
Other outcome; CV events as exploratory 
outcome 
Anand, 2018 (PMID: 29132880) Substudy/already included 
Connolly, 2018 (PMID: 29132879) Substudy/already included 
Kudenchuch, 2016 (PMID: 27043165) Other outcomes 
Perkins, 2018 (PMID: 30021076) Other outcomes 
 
y: year, CV: cardiovascular  
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Table S4. Trial characteristics (n=123). 
Variables Sample (n) (%) 
Journal  
New England Journal of Medicine 83 (67.5) 
Lancet 14 (11.4) 
Journal of the American Medical Association 24 (19.5) 
British Medical Journal 1 (0.8) 
Annals of Internal Medicine 1 (0.8) 
Type of comparator  
 Placebo only 72 (58.5) 
 Active (with the use of placebo) 34 (27.6) 
 Active only 14 (11.4) 
Standard of care (no treatment only)  3 (2.5) 
Trial Design  
Superiority 96 (78.1) 
Non-inferiority/equivalence 27 (21.9) 
Type of funding source  
Industry-sponsored  94 (76.4) 
Non-industry 29 (23.6) 
Type of intervention*   
Antihypertensives/diuretics/heart failure treatments 14 (11.4) 
Antithrombotics/anticoagulants 45 (36.6) 
Lipid-modifying medications 17 (13.8) 
Antidiabetics 16 (13.0) 
Antiinflammatory, antirheumatic, antineoplastic 12 (9.8) 
Cardiac therapy† 3 (2.4) 
Various‡ 16 (13.0) 
*Classified according to ATC Code; †includes antianginal treatment and antiarrhythmic medications 
‡includes antiobesity preparations, medications for the treatment of bone disease, vitamins, and combination 
of different treatments (see Table S3) 
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Table S5. Detailed characteristics of 123 included Randomized Clinical Trials and decriptions of 
reported and not reported co-interventions. 
PMID of 
the 
study 
Interventio
n 
Setting Outcome Co-
intervention
s in the 
protocol 
Co-
interventio
ns 
reported 
Timepoi
nt 
Co-
interventio
ns not 
reported 
F
U 
2173283
5 
 
Nesiritide 
vs Placebo 
Patients 
hospitaliz
ed with 
acute HF  
Composite 
end point 
of 
rehospitali
sation for 
HF or 
death 
“If 
concomitant 
medication 
is used for 
HF, the 
medical 
therapy 
should 
remain as 
stable as 
possible 
during the 
first 6 hours 
after study 
drug 
initiation to 
allow for the 
evaluation 
of any 
potential 
effects of 
study drug. 
Diuretics, 
morphine 
and other 
vasoactive 
drugs may 
be used 
during this 
period if 
clinically 
warranted” 
Informatio
n about 
the use of 
loop 
diuretics, 
inotropic 
agents, 
vasodilato
rs in the 
first 24h in 
table 
First 
24h 
No 
informatio
n on other 
antihypert
ensives, 
aldosteron
e receptor 
blockers 
1 
2976675
0 
Clopidogrel 
and Aspirin 
vs Aspirin 
Patients 
with 
acute 
ischemic 
stroke or 
high risk 
TIA 
Composite 
of major 
ischemic 
events 
(ischemic 
stroke, MI, 
or death 
from an 
ischemic 
vascular 
event) 
“Any 
treatment 
which is 
ongoing 
before 
randomizati
on and/or 
prescribed 
or changed 
during the 
study must 
be 
recorded”  
NI NI No 
informatio
n on 
antihypert
ensives, 
statins in 
patients 
with acute 
stroke 
2.
9 
2716089
2 
 
Tigagrelor 
vs Aspirin 
Patients 
with 
acute 
ischemic 
stroke or 
high risk 
TIA 
Composite 
of stroke, 
MI, death 
“Recording 
of 
concomitant 
medications 
will be made 
at each visit. 
Medications 
of special 
interest 
including 
study 
NI NI No 
informatio
n on 
antihypert
ensives, 
statins in 
patients 
with acute 
stroke 
3 
D
ow
nloaded from
 http://ahajournals.org by on June 17, 2020
 
 
medication, 
other 
antiplatelet 
medications
, PPIs and 
statins will 
be captured 
in detail.  
There are 
no 
restrictions 
to other 
statin 
therapies 
(…). 
Investigator
s are 
advised to 
check lipid 
levels and 
adjust statin 
dosages per 
local 
practice and 
appropriate 
guidelines”  
2380313
6 
 
Aspirin and 
Clopidogrel 
vs Aspirin 
Patients 
with 
acute 
minor 
stroke or 
TIA 
Stroke  “Any drugs 
other than 
those listed 
above are 
permitted 
(including 
anti-
hypertensiv
e 
medications
), if 
considered 
necessary 
for the 
patient, with 
a stable 
dose (when 
possible), at 
the 
discretion of 
the 
Investigator” 
Antiplatele
ts (aspirin, 
ticlopine, 
cilostazole
, 
dipyridam
ole, 
GpIIb/IIIa 
inhibitors), 
heparin, 
anticoagul
ants, 
antihypert
ensives, 
lipid-
lowering, 
hypoglyce
mic 
medicatio
ns 
Through 
day 90 
(end of 
follow-
up) 
 
- 3 
2424761
6 
 
Varespladi
b vs 
Placebo 
Patients 
with ACS 
Composite 
of CV 
mortality, 
nonfatal 
MI, 
nonfatal 
stroke, or 
unstable 
angina 
with 
evidence 
of 
ischemia 
requiring 
Not 
specified in 
the 
puplished 
study 
design 
(extended 
protocol not 
available) 
Aspirin, 
clopidogre
l, 
ticlopidine, 
prasugrel, 
b-
blockers, 
ACEI/ARB
s 
During 
the 
treatme
nt 
period 
 
- 3.
1 
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hospitalisa
tion 
2208219
8 
Dronedaro
ne vs 
Placebo 
Patients 
with high-
risk atrial 
fibrillation 
Composite 
of stroke, 
MI, 
systemic 
embolism, 
or CV 
death 
“Patients 
included in 
the study 
should 
receive the 
usual 
standard 
therapy (…) 
according to 
guidelines. 
Patients 
who 
received 
concomitant 
medications 
during the 
study drug 
period (…) 
will be 
summarized 
using same 
classes as 
those 
already 
defined for 
baseline 
medications
”   
NI 
 
NI No 
informatio
n on 
antihypert
ensives, 
antiplatelet
s or 
statins; No 
informatio
n on 
anticoagul
ation in 
patients 
with atrial 
fibrillation 
3.
5 
2140664
6 
 
High vs 
standard 
dose of 
Clopidogrel 
Patients 
undergoi
ng PCI 
Composite 
of CV 
death, 
nonfatal 
MI, or 
stent 
thrombosi
s 
No 
extended 
protocol 
available; 
published 
study 
design: 
“Concomita
nt 
medications
: aspirin, 
periprocedu
ral 
anticoagulat
ion: left to 
the 
descrition of 
physician” 
Antiplatele
ts, b-
blockers, 
ACE/ARB
s, statin, 
calcium 
channel 
inhibitors 
Periproc
edural 
- 6 
2131675
2 
 
Candesart
an vs 
Placebo 
Patients 
with 
acute 
stroke 
Composite 
of CV 
death, MI, 
or stroke 
No 
extended 
protocol 
available; 
published 
study 
design: “All 
patients are 
given 
standard 
treatment in 
stroke units. 
Therapeutic 
agents other 
Informatio
n about 
other 
antihypert
ensives in 
text 
During 
follow-
up 
No 
informatio
n on 
antiplatelet
s for 
patients 
with acute 
stroke. No 
informatio
n on 
statins 
 
6 
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than ARBs 
can be 
administere
d during the 
treatment 
period.…” 
2178094
6 
 
Apixaban 
vs Placebo 
Patients 
with ACS 
Composite 
of CV 
death, MI 
or 
ischemic 
stroke 
“All subjects 
should 
receive 
evidence-
based post-
ACS care 
according to 
local 
standards of 
care and 
national 
practice 
guidelines 
(ACC/AHA, 
ESC, etc.). 
All subjects 
should 
receive 
single or 
dual 
antiplatelet 
therapy 
based on 
investigator 
discretion”, 
“The use of 
clopidogrel 
and other 
approved 
antiplatelet 
agents will 
be left to 
investigator 
discretion 
and 
according to 
local 
guidelines”; 
Assess 
concomitant 
medications 
at each visit. 
NI NI No 
informatio
n on 
cardiac 
preventive 
treatments 
(antihypert
ensives, 
antiplatelet
s or 
statins)  
7.
9 
2420645
9 
 
Bardoxolon
e vs 
Placebo 
Patients 
with 
diabetes 
and 
chronic 
kidney 
disease 4 
Composite 
of end-
stage 
renal 
disease or 
CV death 
“Investigator
s should not 
reduce or 
discontinue 
ACE 
inhibitors 
and/or 
ARBs 
unless 
indicated 
secondary 
to a medical 
contraindica
tion (e.g. 
hyperkalemi
NI NI No 
informatio
n on 
cardiac 
preventive 
treatments 
(antihypert
ensives, 
antiplatelet
s or 
statins)  
9 
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a). Any 
concomitant 
medication 
with the 
exception of 
those listed 
below may 
be given at 
the 
discretion of 
the 
investigator”
, “the 
prescribing 
information 
for all 
concomitant 
medications 
should be 
reviewed 
carefully”  
2830424
2 
 
Bocozizum
ab vs 
Placebo 
Patients 
at high 
CV risk 
Composite 
nonfatal 
MI, 
nonfatal 
stroke, 
hospitaliza
tion for 
unstable 
angina 
requiring 
urgent 
revascular
ization, or 
CV death 
“All 
permitted 
concomitant 
medications 
should be 
recorded at 
each study 
visit: Lipid 
lowering: all 
patients will 
continue to 
take their 
prescribed 
lipid 
lowering 
treatment”; 
“Other 
concomitant 
treatment 
are 
permitted at 
the 
discretion of 
the 
physician 
according to 
local 
guidelines” 
NI NI No 
informatio
n on 
cardiac 
preventive 
treatments 
(antihypert
ensives, 
antiplatelet
s)  
10 
2976677
2 
 
Rivaroxaba
n vs 
Aspirin 
Patients 
with 
recent 
embolic 
stroke of 
underter
mined 
source 
Stroke or 
systemic 
embolism 
Concomitan
t 
medications 
assessment 
at visit 0, 12 
and end of 
follow-up 
NI NI No 
informatio
n on 
cardiac 
preventive 
medication
s 
(antihypert
ensives, 
antiplatelet
s, statins)  
11 
D
ow
nloaded from
 http://ahajournals.org by on June 17, 2020
 
 
2347874
3 
 
Aliskiren vs 
Placebo 
Patients 
with 
acute HF 
Composite 
of CV 
death of 
HF 
rehospitali
sation 
Not 
extended 
protocol, 
from 
published 
study 
design: 
“Standard 
therapy 
treatment 
will be left to 
the 
discretion of 
the treating 
physician 
but should 
include 
diuretics, 
ACE‐
Inhibitors or 
ARBs, beta‐
blockers, 
and 
aldosterone 
blocking 
agents, 
unless 
contraindica
ted”; “ 
NI NI No 
informatio
n on other 
antihypert
ensives, 
diuretics, 
aldosteron
e receptor 
inhibitors, 
antiplatelet
s, statins 
12 
2795971
3 
 
Low-dose 
Rivaroxaba
n and 
P2Y12 
Inhibitor vs 
very low-
dose 
Rivaroxaba
n 
Patients 
with atrial 
fibrillation 
undergoi
ng PCI 
Composite 
of CV 
death, MI, 
Stroke 
Concomitan
t therapies 
must be 
recorded 
throughout 
the study..”  
NI NI No 
informatio
n on other 
cardiac 
preventive 
treatments 
(antihypert
ensives, 
antiplatelet
s, statins) 
12 
2255019
6 
 
Fish oil 
capsules 
vs Placebo 
Patients 
with 
arteriove
nous 
hemodial
ysis 
grafts 
Composite 
of 
hemodialy
sis graft 
patency 
thrombosi
s and CV 
events 
Not 
extended 
protocol, 
from 
published 
study 
design: 
medication 
review at 
visit 0, 6,12. 
Change in 
antihyperten
sive 
medications
: secondary 
outcome 
NI NI No 
informatio
n on other 
cardiac 
preventive 
treatments 
(antiplatele
ts, statins) 
12 
2130965
7 
 
Apixaban 
vs Aspirin 
Patients 
with atrial 
fibrillation 
Composite 
of stroke 
or 
systemic 
embolism 
Assessment 
of 
concomitant 
medications
: 0, 12, end 
of FU 
Informatio
n for 
aspirin 
and 
clopidogre
l in text 
During 
follow-
up 
No 
informatio
n on 
antihypert
ensives, 
statins 
13
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2840274
5 
 
Ularitide vs 
Placebo 
Patients 
with 
acute HF 
CV death “Required 
medication 
for the 
treatment of 
concomitant 
diseases is 
unrestricted”
. 
Concomitan
t 
medications 
assessment 
at day 30. 
NI NI No 
informatio
n on other 
antihypert
ensives, 
diuretics, 
aldosteron
e receptor 
inhibitors, 
antiplatelet
s, statins 
15 
2990087
4 
 
Dabigatran 
vs Placebo 
Patients 
with 
myocardi
al injury 
after non-
cardiac 
surgery 
Composite 
of 
vascular 
mortality 
and non-
fatal MI, 
non-
hemorrha
gic stroke, 
peripheral 
arterial 
thrombosi
s, 
amputatio
n, and 
symptoma
tic venous 
thromboe
mbolism 
Not 
extended 
protocol, 
from 
published 
study 
design: 
“manageme
nt was left 
to the 
discretion of 
the treating 
physician, 
including 
cardiovascul
ar 
medications
. We 
recommend
ed that all 
patients with 
MINS take 
low-dose 
acetylsalicyli
c acid (ASA) 
and a 
statin”. 
Concomitan
t 
medications 
assessment 
every 6 
months until 
end of FU. 
Antiplatele
ts, 
ACEI/ARB
S, b-
blockers, 
statins 
During 
follow-
up 
 
- 16 
2292093
0 
 
Prasugrel 
vs 
Clopidogrel 
Patients 
with 
NSTEMI, 
who do 
not 
undergo 
PCI 
Composite 
of CV 
death, MI, 
or stroke 
“Other 
cardiac and 
non-cardiac 
medications 
not 
specifically 
excluded 
may be 
administere
d at the 
discretion of 
the treating 
physician”; 
The use of 
all 
concomitant 
NI NI No 
informatio
n on other 
cardiac 
preventive 
treatments 
(antihypert
ensives, 
statins) 
17 
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medications 
will be 
recorded in 
the 
CRF;“The 
effect of 
concomitant 
medications 
on the 
primary 
efficacy 
endpoint will 
be 
assessed by 
conducting 
subgroup 
analyses on 
certain 
medication 
classes” 
3027919
7 
6 vs 12 
months of 
of dual 
treatment 
(Clopidorg
el and 
Aspirin) 
Patients 
with 
STEMI 
treated 
PCI and 
second 
generatio
n 
zotarolim
us-eluting 
stent 
Composite 
of all 
cause 
mortality, 
MI, 
revascular
isation, 
stroke, 
and 
thromboly
sis MI 
major 
bleeding 
Not 
extended 
protocol, 
from 
published 
study 
design: NI 
NI NI No 
informatio
n on other 
cardiac 
preventive 
treatments 
(antihypert
ensives, 
statins) 
18 
2399260
2 
Alogliptin 
vs Placebo 
Patients 
with 
recent 
ACS and 
type 2 
diabetes 
Composite 
of CV 
death, 
nonfatal 
MI, or 
nonfatal 
stroke 
“At each 
study visit, 
subjects will 
be asked 
whether 
they have 
taken any 
medication 
other than 
the study 
medication. 
Investigator
s will be 
encouraged 
to manage 
subjects 
according to 
regional 
guidelines 
for the …. 
…. Subjects 
will be 
instructed 
on proper 
nutrition and 
exercise” 
Medicatio
ns not 
provided. 
Informatio
n about 
lipoprotein 
levels in 
table 
 
End of 
follow-
up 
No 
informatio
n on other 
cardiac 
preventive 
treatments 
(antihypert
ensives, 
antiplatelet
s)  
18 
3029101
3 
Albiglutide 
vs Placebo 
Patients 
with CV 
disease 
Composite 
of CV 
Not 
extended 
protocol, 
Informatio
n on other 
hypoglyce
At 
different 
times of 
No 
informatio
n on other 
19
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and type 
2 
diabetes 
death, MI, 
or stroke 
from 
published 
study 
design: 
“Information 
on the use 
of 
concomitant 
medications 
is captured 
at each visit. 
Usual care 
providers 
are 
encouraged 
to follow 
most-up-to-
date 
guidelines 
for diabetes 
and CV 
disease 
managemen
t according 
to local 
guidelines” 
mic 
medicatio
ns  
 
follow-
up 
cardiac 
preventive 
treatments 
(antihypert
ensives, 
antiplatelet
s, statins)  
2107336
3 
Eplerenon
e vs 
Placebo 
Patients 
with 
systolic 
HF and 
mild 
symptom
s 
Composite 
of CV 
death or 
hospitalisa
tion for HF 
Concomitan
t 
medications
: assessed 
at each visit. 
“Permitted 
concomitant 
medications 
may include 
angiotensin 
ACE-Is, 
ARBs, b-
blockers, 
and 
diuretics.  
Digoxin, 
vasodilators
, and 
inotropes 
may be 
used, as 
clinically 
indicated”  
NI NI No 
informatio
n on other 
antihypert
ensives, 
other 
diuretics, 
antiplatelet
s, statins 
21 
3014693
5 
Rivaroxaba
n vs 
Placebo 
Patients 
with HF 
and 
coronary 
disease 
Composite 
of death 
from any 
cause, MI, 
or stroke 
“For each 
subject, the 
drug identity 
and dose of 
all CV 
therapies 
and proton 
pump 
inhibitors 
taken during 
the index 
hospitalizati
on through 
the end of 
Diuretics, 
ACEI/ARB
s, b-
blockers, 
aldosteron
e receptor 
inhibitors 
Different 
time-
points 
until the 
end of 
follow-
up 
- 21
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the study 
will be 
recorded on 
the 
appropriate 
page of the 
eCRF. 
Subjects 
must be 
receiving at 
a minimum 
for their HF: 
a diuretic 
and RAS 
inhibitor/vas
odilator 
therapy 
(either an 
ACEI, ARB, 
or 
hydralazine/
nitrate 
combination
), and, 
unless 
contraindica
ted, the 
following:Be
ta blockers, 
which 
should be 
titrated to 
the 
maximum 
dose 
recommend
ed by 
current 
guidelines., 
Aldosterone 
antagonists, 
which 
should be 
prescribed 
per 
guideline 
recommend
ations. 
Additional 
standard 
care 
treatments 
for HF and 
CAD 
(except 
anticoagula
nts) as 
prescribed 
by their 
managing 
physician 
are allowed.  
Subjects 
D
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should be 
receiving 
antiplatelet 
therapy as 
standard 
care for 
their CAD” 
2647481
0 
Ranolazine 
vs Placebo 
Patients 
with 
incomplet
e 
revascula
risation 
Composite 
of 
ischemia-
driven 
revascular
isation or 
ischemia-
driven 
hospitalisa
tion 
without 
revascular
isation 
Not 
extended 
protocol, 
from 
published 
study 
design: 
“After PCI, 
participants 
will be 
treated with 
standard 
recommend
ed medical 
therapies, 
including 
antianginal 
therapies 
(other than 
ranolazine) 
per the 
discretion of 
the 
investigator 
(eg, aspirin, 
any second 
antiplatelet 
agent, a 
lipid-
lowering 
agent, b-
blocker, 
calcium-
channel 
blockers, 
nitrates, 
angiotensin-
converting 
enzyme 
inhibitors, 
and/or 
angiotensin 
receptor 
blockers)” 
Concomitan
t 
medications 
assessment 
every 3 
months. 
Antiplatele
ts, 
ACEI/ARB
s, statins, 
b-
blockers, 
calcium 
channel 
blockers, 
nitrate, 
anti-
ischemic 
drugs 
6 and 
12 
months 
 
No 
informatio
n on 
cardiac 
preventive 
treatments 
(antihypert
ensives, 
antiplatelet
s or 
statins) at 
the end of 
follow-up 
21
.2 
2187097
8 
Apixaban 
vs Warfarin 
Patients 
with atrial 
fibrillation 
at risk for 
stroke 
Composite 
of stroke 
(ischemic 
or 
hemorrha
gic) or 
“The 
frequency of 
subjects 
receiving 
concomitant 
medications 
NI NI No 
informatio
n on 
antiplatelet
s, 
antihypert
21
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systemic 
embolism 
after 
randomizati
on will be 
summarized 
by treatment 
group, 
medication 
class (anti-
platelet, 
anti-
coagulant/V
KA, anti-
arrhythmic, 
diuretic, ace 
inhibitor, 
beta 
blocker, 
alpha 
blocker, 
calcium 
channel 
blocker, 
ARB, lipid 
lowering, 
CYP3A4 
inhibitor, 
hypoglycemi
c, anti-
depressant, 
NSAID, 
other) and 
drug name” 
ensives, 
statins  
2884419
2 
Rivaroxaba
n and 
Aspirin vs 
Aspirin  
Rivaroxaba
n vs 
Aspirin 
Patients 
with 
stable CV 
disease 
Composite 
of CV 
death, 
stroke, or 
MI 
“Subjects 
may receive 
all 
medications 
that their 
treating 
physicians 
believe are 
necessary” 
Concomitan
t 
medications 
assessed at 
screening, 9 
months and 
end of FU. 
NI NI No 
Informatio
n on other 
cardiac 
preventive 
treatments 
(antihypert
ensives, 
statins)  
23 
2183095
7 
Rivaroxaba
n vs 
Warfarin 
Patients 
with 
nonvalvul
ar atrial 
fibrillation 
at risk of 
stroke 
Composite 
of stroke 
or 
systemic 
embolism 
“All 
medications 
not 
restricted or 
disallowed, 
as outlined 
below, are 
permitted” 
“Appropriate 
caution 
should be 
exercised 
with any 
changes in 
diet or for 
Only 
informatio
n about 
aspirin-
use in text 
 
At some 
point 
during 
the 
study 
No 
informatio
n on other 
cardiac 
preventive 
treatments 
(antihypert
ensives, 
statins)  
23
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over-the-
counter or 
prescription 
medications 
that might 
affect 
warfarin 
dosing..inclu
ding the 
performanc
e of INR 
testing as 
necessary 
to adjust 
dosing” 
Concomitan
t 
medications 
assessed at 
each visit. 
2736787
6 
Escitalopra
m vs 
Placebo 
Patients 
with HF 
and 
depressio
n  
Composite 
of all 
cause 
death or 
hospitaliza
tion 
Not 
extended 
protocol, 
from 
published 
study 
design: NI 
ACEI/ARB
s, b-
blockers 
 
At 3 
months 
 
No 
informatio
n on 
diuretics, 
aldosteron
e receptor 
inhibitors, 
antiplatelet
s, statins  
24 
2468206
9 
Aleglitazar 
vs Placebo 
Patients 
with 
recent 
ACS and 
type 2 
diabetes 
Composite 
of CV 
death, 
nonfatal 
MI, 
nonfatal 
stroke 
Extended 
protocol not 
available, 
from 
published 
study 
design: 
“Although 
statins may 
be adjusted 
throughout 
the trial 
according to 
LDL-C 
levels, 
investigator
s are 
encouraged 
to maintain 
other 
background 
lipid-
modulating 
therapy 
(niacin, fish 
oil, bile acid 
sequestrant
s) at stable 
doses 
during the 
trial. 
Patients are 
counseled 
on diet and 
NI NI No 
informatio
n on other 
cardiac 
preventive 
treatments 
(antihypert
ensives, 
antiplatelet
s, statins)  
24 
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exercise 
based on 
guidelines”  
2860560
3 
Degludec 
vs Glargine 
 
Patients 
with type 
2 
diabetes 
Composite 
of major 
CV event 
(death 
from CV 
causes, 
nonfatal 
MI, or 
nonfatal 
stroke) 
“Relevant 
concomitant 
medications 
… diabetes 
and 
cardiovascul
ar related 
diseases, 
(for example 
antihyperten
sives, lipid-
lowering 
agents, 
aspirin and 
other 
antiplatelet 
agents) 
taken at trial 
entry and 
during the 
trial must be 
recorded” 
Lipid 
lowering, 
antihypert
ensives, 
anticoagul
ants, 
antiplatele
ts, 
diuretics, 
hypoglyce
mic 
medicatio
ns 
 
At the 
end of 
follow-
up 
 
- 24 
2663014
3 
Lixisenatid
e vs 
Placebo 
Patients 
with 
recent 
ACS and 
type 2 
diabetes 
Composite 
of CV 
death, MI, 
stroke, or 
hospitalisa
tion for 
unstable 
angina 
“Treatments 
in addition 
to the IP 
should be 
kept to a 
minimum 
during the 
study. 
However, if 
these are 
considered 
necessary 
for the 
patient’s 
welfare and 
are unlikely 
to interfere 
with the IP, 
they may be 
given at the 
discretion of 
the 
Investigator, 
with a stable 
dose (when 
possible)” 
“Change in 
concomitant 
medications 
will be 
assessed at 
each visit. 
The prior, 
on-study, 
and post-
study 
medications 
will be 
NI 
 
NI No 
informatio
n on other 
cardiac 
preventive 
treatments 
(antihypert
ensives, 
antiplatelet
s, statins) 
25 
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presented 
on the 
randomized 
population.  
Medications 
will be 
summarized 
by treatment 
group” 
2763318
6 
 
Semaglutid
e vs 
Placebo 
Patients 
with type 
2 
diabetes 
Composite 
of CV 
death, 
nonfatal 
MI, 
nonfatal 
stroke 
“A broad 
spectrum of 
concomitant 
glucose-
lowering 
treatments, 
as well as 
other 
treatments 
for co-
morbidities 
and 
cardiovascul
ar risk 
factors can 
be 
introduced 
in subjects 
based on 
individual 
requirement
s and at 
investigator’
s discretion” 
Lipid 
lowering, 
antihypert
ensives, 
anticoagul
ants, 
antiplatele
ts, 
diuretics, 
hypoglyce
mic 
medicatio
ns 
At the 
end of 
follow-
up 
 
- 25
.2 
2399260
1 
 
Saxagliptin 
vs Placebo 
Patients 
with CV 
disease 
or at high 
CV risk 
and type 
2 
diabetes 
Composite 
of CV 
death, MI, 
or 
ischemic 
stroke 
“All patients 
will be 
treated to 
regional 
standards of 
care for 
cardiovascul
ar risk 
factors (eg, 
blood 
pressure, 
lipids) and 
HbA1c.  
Investigator
s will be 
duly 
informed of 
this 
requirement 
via…. 
Recording 
of 
concomitant 
medication 
with a 
duration of 
≥3 months 
in the 
appropriate 
sections of 
Lipid 
lowering, 
antihypert
ensives, 
antiplatele
ts, 
diuretics, 
hypoglyce
mic 
medicatio
ns 
 
At 1-
year, 2-
year 
and at 
the end 
of 
follow-
up 
 
- 25
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… will be 
according to 
type of 
medication” 
2851462
4 
 
Evacetrapi
b vs 
Placebo 
Patients 
at high 
CV risk 
Composite 
of CV 
death, MI, 
stroke, 
coronary 
revascular
ization, or 
hospitaliza
tion for 
unstable 
angina 
“Patients 
will be 
allowed to 
take any 
concomitant 
medications 
required 
except 
those listed 
in the …..  
These 
therapies 
may 
include, but 
are not 
limited to, 
aspirin, 
other 
antiplatelet 
agents, H2 
receptor 
blockers, 
proton 
pump 
inhibitors, 
antihyperten
sives, and 
appropriate 
diet and 
exercise 
and other 
nonpharmac
ologic 
measures” 
NI NI No 
informatio
n on other 
cardiac 
preventive 
treatments 
(antihypert
ensives, 
antiplatelet
s)  
26 
2830422
4 
 
Evolocuma
b vs 
Placebo 
Patients 
with CV 
disease 
Composite 
of CV 
death, MI, 
stroke, 
hospitaliza
tion for 
unstable 
angina, or 
coronary 
revascular
ization 
“Throughout 
the study, 
investigator
s may 
prescribe 
any 
concomitant 
medications 
or 
treatments 
deemed 
necessary 
to provide 
adequate 
supportive 
care. 
Subjects 
must remain 
on the same 
dose of 
atorvastatin 
with or 
without 
ezetimibe 
as taken at 
Only 
informatio
n about 
statins 
and 
ezetimibe 
During 
follow-
up 
 
No 
informatio
n on other 
cardiac 
preventive 
treatments 
(antihypert
ensives, 
antiplatelet
s) 
26 
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baseline 
from end of 
screening 
until the end 
of the study” 
3041847
5 
 
Linagliptin 
vs Placebo 
Patients 
with type 
2 
diabetes 
and high 
CV and 
renal risk 
Composite 
of CV 
death, 
nonfatal 
MI, or 
nonfatal 
stroke 
Not 
extended 
protocol, 
from 
published 
study 
design: 
“Investigator
s were also 
encouraged 
to treat all 
other CV 
risk factors 
(e.g. 
dyslipidemia
, 
hypertensio
n, 
albuminuria, 
smoking) in 
accordance 
with optimal 
local or 
regional 
guidelines 
and 
standards of 
care. 
Ultimately, 
changes in 
medication 
were at the 
discretion of 
the 
investigator 
and/or 
treating 
clinician” 
Lipid 
lowering, 
ACEI/ARB
S, renin 
inhibitors, 
diuretics, 
b-
blockers, 
calcium 
channel 
inhibitors,  
anticoagul
ants, 
antidiabeti
cs 
 
Postbas
eline 
 
- 26
.4 
2517601
5 
 
Angiotensi
n-
neprilysin 
inhibition 
vs enalapril 
Patients 
with class 
II, III, or 
IV HF 
and an 
ejection 
fraction 
of 40% 
Composite 
of CV 
death or 
HF 
hospitaliza
tion 
“The patient 
should be 
on an 
optimal 
medical 
regimen of 
background 
HF 
medications
. This must 
include an 
individually 
optimized 
dose of a b-
blocker (i.e., 
maximally 
tolerated 
dose) at a 
stable dose 
for at least 4 
NI NI No 
informatio
n on 
diuretics, 
aldosteron
e receptor 
inhibitors, 
antiplatelet
s, statins 
27 
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weeks prior 
to study 
entry, 
unless 
contraindica
ted or not 
tolerated. 
Every effort 
should be 
made to 
keep the 
dose level 
of these 
background, 
life-saving 
HF 
medications 
stable 
throughout 
the entire 
study. 
However, if 
the patient’s 
condition 
warrants a 
change in 
any of these 
medications
, it is 
allowed at 
the 
discretion of 
the study 
investigator.  
Diuretics 
may be 
used and 
may be 
adjusted 
throughout 
the length of 
the study at 
the 
discretion of 
the 
investigator” 
3041561
0 
 
Methotrexa
te vs 
Placebo 
Patients 
with CV 
disease 
and type 
2 
diabetes 
or 
metabolic 
syndrom
e 
Composite 
of CV 
death, MI, 
or stroke 
NI NI NI No 
informatio
n on other 
cardiac 
preventive 
treatments 
(antihypert
ensives, 
antiplatelet
s, statins)  
27
.6 
2517613
6 
 
Ivabradine 
vs Placebo 
Patients 
with 
stable 
coronary 
artery 
disease 
Composite 
of CV 
death or 
nonfatal 
MI 
“Patients 
selected for 
the study 
should 
receive the 
treatments 
appropriate 
NI NI No 
informatio
n on other 
cardiac 
preventive 
treatments 
(antihypert
27
.8 
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to their 
cardiovascul
ar condition. 
The 
concomitant 
treatments 
received by 
patients 
(and their 
respective 
doses) 
should not 
be modified 
during the 
study, 
unless there 
is a clinical 
need” 
ensives, 
antiplatelet
s, statins) 
2695440
8 
 
Naltrexone
-bupropion 
group vs 
Placebo 
Overweig
ht and 
obese 
patients 
with high 
CV risk  
MACE, 
defined as 
CV death, 
nonfatal 
stroke, or 
nonfatal 
MI 
“The 
incidence of 
the use of 
certain 
medications 
(e.g., 
statins, 
antihyperten
sive agents, 
and 
antidiabetic 
agents) at 
screening, 
Visit 8 
(Week 
52)… and at 
study 
medication 
discontinuati
on … as 
applicable) 
will be 
summarized 
for each 
treatment 
group.The 
incidence of 
subjects 
with a 
change in 
these 
medications 
…may also 
be 
summarized
” 
Informatio
n 
regarding 
CV risk 
factors 
and 
concomita
nt 
medicatio
ns 
 
During 
follow-
up 
No 
informatio
n on 
potential 
differences 
between 
groups in 
text 
27
.8 
2347333
8 
 
Darbepoeti
n alfa vs 
Placebo 
Patients 
with 
systolic 
heart 
failure 
and 
anemia 
Composite 
of death 
from any 
cause or 
hospitalisa
tion for 
worsening 
HF 
“Throughout 
the study, 
investigator
s may 
prescribe 
any 
concomitant 
medications 
or 
Other 
treatments 
presented 
in the text 
During 
follow-
up 
No 
informatio
n on other 
antihypert
ensives, 
other 
diuretics, 
aldosteron
28 
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treatments 
deemed 
necessary 
to provide 
adequate 
supportive 
care except 
as specified 
in Section 
6.4.  
Information 
on 
concomitant 
therapy will 
be collected 
on the 
appropriate 
CRF.  
Iron will be 
administere
d as 
tolerated 
according to 
…  
Administrati
on of iron 
therapy will 
be recorded 
on the CRF” 
e receptor 
inhibitors, 
antiplatelet
s, statins 
2161652
7 
 
Terutroban 
vs Aspirin 
Patients 
with 
recent 
ischemic 
stroke or 
TIA 
Composite 
of fatal or 
non-fatal 
ischemic 
stroke, 
fatal or 
non-fatal 
MI, or 
other 
vascular 
death 
Not 
extended 
protocol, 
from 
published 
study 
design: 
“Clinical 
examination 
is 
performed, 
and 
concomitant 
treatments 
are 
recorded at 
every visit” 
“Furtherm
ore, we 
recorded 
no 
difference
s between 
groups in 
mean 
blood 
pressure, 
heart rate, 
or 
laboratory 
parameter
s 
throughou
t the study 
(data not 
shown)” 
Througo
ut the 
study 
- 28
.3 
2425135
9 
Edoxaban 
vs Warfarin 
Patients 
with atrial 
fibrillation 
Composite 
of stroke 
or 
systemic 
embolism 
“There are 
no 
concomitant 
medications 
required as 
part of the 
study 
design” 
 
NI NI No 
informatio
n on other 
cardiac 
preventive 
treatments 
(antihypert
ensives, 
antiplatelet
s, statins) 
29
.8 
2539965
8 
 
12 or 30 
months of 
dual 
Patients 
who had 
undergon
e PCI 
Composite 
of stent 
thrombosi
s and 
“All 
anticoagula
nt and 
antiplatelet 
NI NI No 
informatio
n on other 
cardiac 
30 
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antiplatelet 
therapy 
with 
drug-
eluting 
stents 
MACE 
and 
cerebrova
scular 
events 
(composit
e of death, 
MI, stroke) 
concomitant 
medications 
must be 
recorded in 
the subject’s 
medical 
record and 
on the 
eCRFs.  In 
addition to 
APT, beta-
blockers, 
statins, 
ACEIs, 
ARBs, 
NSAIDs, 
COX-2, 
PPIs and 
warfarin will 
be captured 
on the 
eCRF. The 
information 
related to 
the 
concomitant 
medications 
will be 
recorded .. 
through the 
33 month 
follow up 
visit” 
preventive 
treatments 
(antihypert
ensives, 
statins) 
2244342
7 
Vorapaxar 
vs Placebo 
Patients 
with a 
history of 
CV 
disease 
Composite 
of CV 
death, MI, 
or stroke 
“The 
potential 
influence of 
baseline risk 
factors and 
concomitant 
therapies 
such as 
statins, 
thienopyridi
nes, and 
aspirin 
dosing on 
the 
occurrences 
of the 
primary and 
key 
secondary 
efficacy 
endpoints 
will be 
explored 
using the 
Cox 
proportional
-hazard 
model” 
NI NI No 
informatio
n on other 
cardiac 
preventive 
treatments 
(antihypert
ensives, 
antiplatelet
s, statins) 
30 
2517351
6 
Darapladib 
vs Placebo 
Patients 
with 
Composite 
of 
“It is 
recommend
No 
difference 
 No 
informatio
30 
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recent 
ACS 
coronary 
heart 
disease 
death, MI, 
or urgent 
coronary 
revascular
ization for 
MI 
ed that 
subjects 
enrolled in 
the SOLID-
TIMI 52 trial 
be treated 
according to 
the existing 
guidelines 
for patients 
after ACS. 
The 
background 
use of 
evidence-
based 
medications 
including 
statins, 
antiplatelet 
drugs, and 
β-blockers 
is closely 
monitored 
throughout 
the course 
of the trial” 
between 
the groups 
in lipids or 
blood 
pressure 
in the text 
 
n on 
antiplatelet
s 
2207719
2 
Rivaroxaba
n vs 
Placebo 
Patients 
with 
recent 
ACS 
Composite 
of CV 
death, MI 
or stroke 
“For each 
subject, .. all 
concomitant 
therapies .. 
will be 
recorded on 
the 
appropriate 
page of the 
CRF. The 
duration of 
dual 
antiplatelet 
treatment is 
at the 
discretion of 
the 
investigator 
and may 
vary 
depending 
on the 
subject's 
diagnosis or 
whether a 
bare metal 
stent or 
drug eluting 
stent is 
implanted. 
All other 
concomitant 
medication 
use is at the 
discretion of 
the 
NI NI No 
informatio
n on other 
cardiac 
preventive 
treatments 
(antihypert
ensives 
antiplatelet
s, statins) 
31 
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managing 
clinician. It 
is advised 
that the 
appropriate 
guideline 
recommend
ations be 
followed for 
all other 
concomitant 
medication” 
2312625
2 
Dalcetrapib 
vs Placebo 
Patients 
with 
recent 
ACS 
Composite 
of death 
from 
coronary 
heart 
disease, 
nonfatal 
MI, 
ischemic 
stroke, 
unstable 
angina, or 
cardiac 
arrest with 
resuscitati
on 
“Patients 
should 
receive 
contempora
ry evidence-
based 
medical 
care for 
ACS, 
including 
anti-
platelets, b-
blockers, 
ACEIs, and 
statins, and 
medication 
for optimal 
control of 
hypertensio
n, angina, 
and 
diabetes. 
Patients 
should also 
receive 
instructions 
on a heart 
healthy diet. 
Patients 
should also 
receive 
counseling 
on 
appropriate 
life style 
modification
s such as 
weight 
control, 
physical 
activity, 
smoking 
cessation 
etc. The use 
of any 
concomitant 
medication 
will be 
recorded” 
Antiplatele
ts (aspirin, 
clopidogre
l, 
ticlopidine, 
prasugrel)
, statins, 
b-
blockers, 
ACEI/ARB
s, 
diuretics, 
calcium 
channel 
blockers 
 
At 3 ,12, 
24, 36 
months 
 
- 31 
D
ow
nloaded from
 http://ahajournals.org by on June 17, 2020
 
 
2952797
4 
Febuxostat 
vs 
Allopurinol 
Patients 
with gout 
and CV 
disease 
Composite 
of CV 
death, 
nonfatal 
MI, 
nonfatal 
stroke, or 
unstable 
angina 
with 
urgent 
revascular
ization 
“Concomita
nt 
medications 
assessed at 
each visit” 
Antiplatele
ts (aspirin, 
clopidogre
l), lipid-
lowering, 
ACEI/ARB
s 
 
At 12, 
24, 36 
months 
 
- 32 
2578144
0 
Thienopyri
dine vs 
Placebo 
Patients 
following 
treatment 
with 
bare-
meta 
stents or 
drug-
eluting 
stents 
Composite 
of death, 
MI, stroke 
“Demograph
ic, clinical, 
and 
procedural 
information 
at the time 
of 
enrollment 
are 
captured as 
well as 
subsequent 
clinical end 
points, 
serious 
adverse 
events, 
concomitant 
medications
, and 
antiplatelet 
therapy 
compliance” 
NI NI No 
informatio
n on other 
cardiac 
preventive 
treatments 
(antihypert
ensives, 
statins) 
32
.5 
2312137
8 
 
Aliskiren vs 
Placebo 
Patients 
with type 
2 
diabetes 
and CV 
or renal 
disease 
Composite 
of CV 
death or 
cardiac 
arrest with 
resuscitati
on; 
nonfatal 
MI; 
nonfatal 
stroke; 
unplanned 
HF 
hospitalisa
tion; renal 
hard 
endpoints 
“Patients 
should be 
treated with 
the target 
dose of the 
medications 
as per the 
guidelines 
relevant to 
his/her 
medical 
history and 
concomitant 
conditions. 
Concomitan
t treatment 
must 
include an 
ACEI or an 
ARB and 
treatment 
with statins 
is 
recommend
ed”  
ACEI/ARB
S, b-
blockers, 
diuretics, 
calcium 
channel 
blockers 
 
At 12, 
24, 36 
months 
 
No 
informatio
n on 
antiplatelet
s 
32
.9 
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2577326
8 
 
Tigagrelor 
vs Placebo 
 
Patients 
with prior 
MI 
Composite 
of CV 
death, MI, 
or stroke 
“Concomita
nt therapy 
with 
simvastatin 
or lovastatin 
at doses 
higher than 
40 mg daily 
is not 
permitted. 
There are 
no 
restrictions 
to other 
statin 
therapies 
(ie, doses of 
simvastatin 
or lovastatin 
≤40 mg 
daily or any 
dose of any 
other statin 
is 
permitted)” 
NI NI No 
informatio
n on other 
cardiac 
preventive 
treatments 
(antihypert
ensives, 
statins) 
33 
3040357
4 
Alirocumab 
vs Placebo 
Patients 
with prior 
ACS 
Composite 
of death 
from 
coronary 
heart 
disease, 
nonfatal 
MI, fatal or 
nonfatal 
ischemic 
stroke, or 
unstable 
angina 
requiring 
hospitaliza
tion 
 
“All patients 
should 
receive 
contempora
ry evidence-
based 
treatment 
for ACS and 
chronic 
coronary 
heart 
disease as 
described in 
regional 
professional 
guidelines, 
including, 
but not 
limited to 
anti-platelet 
agents, b-
blockers, 
ACEIs or 
ARBs, and 
treatments 
for diabetes, 
hypertensio
n, and 
smoking” 
NI NI No 
informatio
n on other 
cardiac 
preventive 
treatments 
(antihypert
ensives, 
antiplatelet
s) 
33
.6 
2795971
6 
Celecoxib 
vs 
Naproxen 
Celecoxib 
vs 
Ibuprofen 
Patients 
at 
increased 
CV risk 
Composite 
outcome 
of CV 
death 
(including 
hemorrha
gic death), 
nonfatal 
MI, or 
“Concomita
nt 
medications 
assessed at 
each visit” 
NI NI No 
informatio
n on other 
cardiac 
preventive 
treatments 
(antihypert
ensives, 
34
.1 
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nonfatal 
stroke 
antiplatelet
s, statins) 
2208534
3 
Niacin vs 
Placebo 
Patients 
with CV 
disease 
and low 
HDL 
Composite 
of death 
from 
coronary 
heart 
disease, 
nonfatal 
MI, 
ischemic 
stroke, 
hospitalisa
tion for an 
acute 
coronary 
syndrome, 
or 
symptom-
driven 
coronary 
or cerebral 
revascular
ization 
 
“Concomita
nt drugs not 
allowed: 
Lipid-
lowering 
drugs (other 
than the 
investigation
al drugs), 
such as 
statins, bile-
acid 
sequestrant
s, fish oils, 
cholesterol 
absorption 
inhibitors 
(e.g., 
ezetimibe, 
except for 
its use as 
described 
above to 
achieve 
study 
protocol 
treatment 
goals for 
LDL-C), 
fibrates” 
 
Adequate 
descriptio
n of other 
preventive 
treatments 
in text 
During 
follow-
up 
- 36 
2605298
4 
Sitagliptin 
vs Placebo 
Patients 
with type 
2 
diabetes 
and CV 
disease 
Composite 
of CV 
death, 
nonfatal 
MI, 
nonfatal 
stroke, or 
hospitalisa
tion for 
unstable 
angina 
“In 
accordance 
with 
standard 
guidelines 
for care in 
all countries 
participating 
in the study, 
it is 
anticipated 
that all 
subjects will 
receive 
counseling 
about 
appropriate 
diet and 
exercise 
intervention
s as part 
ofusual 
care. 
Concomitan
t 
medications 
will be used 
at the 
discretion of 
the usual 
NI NI No 
informatio
n on other 
cardiac 
preventive 
treatments 
(antihypert
ensives, 
antiplatelet
s, statins)  
36 
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care 
physician, 
who will be 
informed of 
the 
participant’s 
enrollment 
in the study, 
the use of 
blinded 
study 
medication, 
and the 
classes of 
AHAs which 
are 
contraindica
ted during 
the study 
period. 
Usual care 
physicians 
will be 
encouraged 
to follow 
guidelines 
for care 
based upon 
local and 
institutional 
practice 
patterns and 
any relevant 
published 
practice 
guidelines” 
2704377
4 
Aliskiren vs 
Enalapril 
Aliskiren/E
nalapril vs 
Enalapril 
Patients 
with HF 
and 
reduced 
ejection 
fraction 
Composite 
of CV 
death or 
HF 
hospitalisa
tion 
“Every effort 
should be 
made by the 
investigator 
to keep the 
dose level 
of each 
patient’s 
background 
heart failure 
medications 
(such as 
ARB’s, beta 
blocker) 
stable 
throughout 
the entire 
study 
duration. 
However, if 
the clinical 
condition of 
the patient 
warrants a 
change in 
any of these 
medications
NI NI No 
informatio
n on 
diuretics, 
antiplatelet
s, statins 
36
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, it is 
allowed at 
the 
discretion of 
the study 
investigator.  
Concomitan
t use of 
aldosterone 
receptor 
antagonists 
and ARB is 
prohibited” 
2891023
7 
 
Exenatide 
vs Placebo 
Patients 
with type 
2 
diabetes 
Composite 
outcome 
death from 
CV 
causes, 
nonfatal 
MI, or 
nonfatal 
stroke 
“Concomita
nt 
medications 
will be used 
at the 
discretion of 
the usual 
care 
physician 
(or 
investigator 
if also the 
usual care 
physician), 
…. Usual 
care 
physicians 
will be 
encouraged 
to follow 
guidelines 
for care 
based upon 
local and 
institutional 
practice 
patterns and 
any relevant 
published 
practice 
guidelines…
”  
Lipid 
lowering, 
antihypert
ensives, 
anticoagul
ants, 
antiplatele
ts, 
hypoglyce
mic 
medicatio
ns 
 
During 
follow-
up 
 
- 38
.4 
2637897
8 
Empagliflo
zin vs 
Placebo  
 
Patients 
with type 
2 
diabetes 
and high 
CV risk 
Composite 
outcome 
of CV 
death, 
nonfatal 
MI, or 
nonfatal 
stroke 
“Beginning 
at the 
Screening 
Visit and 
every visit 
thereafter 
(except 
follow-up 
visit), 
patients will 
receive diet 
and 
exercise 
counselling 
based on 
local diet 
recommend
ations.  
Lipid 
lowering, 
antihypert
ensives, 
anticoagul
ants, 
antiplatele
ts, 
hypoglyce
mic 
medicatio
ns  
Postbas
eline 
 
- 38
.4 
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Concomitan
t 
medications 
will be 
documented 
at each 
visit” 
2655127
2 
Intensive 
BP 
Lowering 
vs Control 
Persons 
with a 
systolic 
blood 
pressure 
of 130 
mm Hg or 
higher 
and an 
increased 
CV risk, 
but 
without 
diabetes 
Composite 
of MI, 
other 
acute 
coronary 
syndrome
s, stroke, 
HF, or CV 
death 
“Information 
regarding 
the 
participants’ 
concomitant 
non-study 
medication 
therapy is 
collected .. 
at annual 
followup 
visits….Alth
ough data 
are 
collected on 
all current 
therapies, 
emphasis is 
placed on 
concurrent 
antihyperten
sive, 
cardiovascul
ar, chronic 
kidney 
disease and 
dementia 
medications 
as well as 
background 
risk 
reduction 
therapy 
such as 
aspirin and 
lipid-
lowering 
drugs” 
NI NI No 
informatio
n on other 
cardiac 
preventive 
treatments 
(antiplatele
ts, statins, 
which 
antihypert
ensives 
per group) 
39
.1 
3014594
1 
 
Lorcaserin 
vs Placebo 
Overweig
ht or 
obese 
patients 
with CV 
disease 
or 
multiple 
CV risk 
factors 
Composite 
of CV 
death, MI, 
or stroke 
“Medication
s for the 
treatment of 
hypertensio
n, 
dyslipidemia
, or diabetes 
may be 
started, 
discontinue
d, or 
adjusted 
during the 
study 
according to 
local 
standards of 
care if, in 
Informatio
n on CV 
risk 
factors 
 
End of 
follow-
up 
No 
informatio
n on other 
cardiac 
preventive 
treatments 
(antihypert
ensives, 
antiplatelet
s) 
39
.6 
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the 
judgment of 
the 
investigator 
or the 
subject’s 
physician, 
such a 
change is 
medically 
indicated” 
2471668
0 
Spironolact
one vs 
Placebo 
Patients 
with heart 
failure 
and a 
preserve
d left 
ventricula
r ejection 
fraction 
Composite 
of CV 
death, 
aborted 
cardiac 
arrest, or 
hospitalisa
tion for the 
managem
ent of HF 
“Subjects 
will be 
treated with 
other 
medications 
at the 
discretion of 
their 
cardiologist 
and/or 
primary care 
provider. All 
medications 
will be 
recorded on 
the study 
forms. 
Concomitan
t 
medications 
are 
assessed 
regularly” 
NI NI No 
informatio
n on other 
cardiac 
preventive 
treatments 
(antihypert
ensives, 
diuretics, 
aldosteron
e receptor 
inhibitors, 
antiplatelet
s, statins) 
39
.6 
2293131
5 
 
Aspirin and 
Clopidogrel 
vs Aspirin 
Patients 
with 
recent 
lacunar 
stroke 
Composite 
of 
recurrent 
stroke, 
(ischemic 
stroke and 
intracrania
l 
hemorrha
ge) 
NI Statins  
(antihypert
ensives as 
part of 2x2 
factorial) 
At any 
time of 
follow-
up 
- 40
.8 
2255110
5 
Warfarin vs 
Aspirin 
Patients 
with HF 
and 
reduced 
ejection 
fraction 
Composite 
of 
ischemic 
stroke, 
intracerebr
al 
hemorrha
ge, death 
from any 
cause 
 
“Unless 
contraindica
ted, all 
patients 
should 
receive 
optimal 
doses of 
angiotensin-
converting 
enzyme 
inhibitors or 
equivalent 
and 
betaadrener
gic 
antagonists.  
NI NI No 
informatio
n on 
diuretics, 
aldosteron
e receptor 
inhibitors, 
statins 
42 
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 4.4.3 
Managemen
t of Vascular 
Risk Factors 
All patients 
will receive 
optimal 
treatment 
for 
hypertensio
n, diabetes 
mellitus and 
hypercholes
terolemia 
(See 
Procedure 
Manual)” 
2860560
8 
Canaglifloz
in vs 
Placebo 
Patients 
with type 
2 
diabetes 
Composite 
of CV 
death, 
nonfatal 
MI, or 
nonfatal 
stroke 
“All 
therapies 
different 
from the 
study drug 
must be 
recorded in 
the 
concomitant 
therapy 
section … of 
the CRF.  
During the 
2-week 
single-blind 
placebo run-
in period, 
investigator
s should 
adjust the 
subject’s 
regimen as 
needed to 
optimize the 
subject’s CV 
risk factors 
and thereby 
to reduce 
the need for 
adjustments 
of 
medications 
after 
randomizati
on” 
NI NI No 
informatio
n on other 
cardiac 
preventive 
treatments 
(antihypert
ensives, 
antiplatelet
s, statins)  
43
.2 
2372615
9 
 
Intensive 
blood 
pressure 
lowering vs 
Control 
Patients 
with 
recent 
lacunar 
stroke 
Stroke 
(including 
ischemic 
strokes 
and 
intracrania
l 
hemorrha
ges) 
NI Mean 
number of 
antihypert
ensives 
(ACEI/AR
Bs, 
diuretics, 
calcium 
channel 
blockers, 
b-
At last 
visit 
 
- 44
.4 
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blockers), 
statins 
2884575
1 
 
Canakinum
ab 50 mg 
vs Placebo 
Canakinum
ab 150 mg 
vs Placebo 
Canakinum
ab 300 mg 
vs Placebo 
 
Patients 
with 
previous 
MI and a 
high-
sensitivity 
C-
reactive 
protein 
level of 2 
mg or 
more per 
liter 
Composite 
of nonfatal 
MI, 
nonfatal 
stroke, or 
CV death 
“All 
medications 
and 
significant 
non-drug 
therapies 
(including 
physical 
therapy and 
blood 
transfusions
) taken 
within 30 
days of 
screening 
and 
administere
d after the 
patient has 
signed 
informed 
consent 
must be 
listed on the 
appropriate 
Concomitan
t 
Medications 
and or 
Procedures 
and 
Significant 
Non-Drug 
Therapies 
eCRF 
Prior & 
Concomitan
t  
Antidiabetic 
& CVD 
Medications
: assessed 
at each 
visit” 
NI NI No 
informatio
n on other 
cardiac 
preventive 
treatments 
(antihypert
ensives, 
antiplatelet
s, statins) 
44
.4 
2467895
5 
 
Darapladib 
vs Placebo 
Patients 
with 
stable 
coronary 
heart 
disease 
Composite 
of CV 
death, MI, 
or stroke 
“All 
concomitant 
medications 
taken during 
the study 
will be 
recorded in 
the eCRF. 
The use of 
concomitant 
statin 
therapy will 
be ….” 
Following 
informatio
n in the 
text “LDL 
levels and 
BP were 
balanced 
at the end 
of the 
study” 
 
End of 
follow-
up 
No 
informatio
n on 
antiplatelet
s 
44
.4 
2729542
7 
 
Liraglutide 
vs Placebo 
Patients 
with type 
2 
Composite 
of CV 
death, 
“Non-
investigation
al drugs that 
Lipid 
lowering, 
antihypert
At the 
end of 
- 45
.6 
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diabetes 
and high 
CV risk 
nonfatal 
MI, 
nonfatal 
stroke 
are required 
will be 
prescribed 
to trial 
subjects in 
the usual 
fashion 
according to 
local health 
plans. 
Concomitan
t medication 
will be 
recorded at 
every visit, if 
any 
changes…H
owever, the 
final choice 
of 
concomitant
therapy and 
glucose-
lowering 
intensificatio
n modalities 
will be at 
Investigator’
s discretion” 
ensives, 
anticoagul
ants, 
antiplatele
ts, 
diuretics, 
hypoglyce
mic 
medicatio
ns 
 
follow-
up 
 
2501468
6 
 
Niacin vs 
Placebo 
Patients 
with CV 
disease  
Composite 
of nonfatal 
MI, death 
from 
coronary 
causes, 
stroke or 
arterial 
revascular
isation 
Only 
information 
about 
statins 
NI NI No 
informatio
n on other 
cardiac 
preventive 
treatments 
(antihypert
ensives, 
antiplatelet
s) 
46
.8 
3053521
7 
Alfacalcidol 
vs control 
Patients 
with 
chronic 
kidney 
disease 
Composite 
of fatal 
and 
nonfatal 
CV events 
(MI, 
hospitaliza
tions for 
congestive 
HF, 
stroke, 
aortic 
dissection/
rupture, 
amputatio
n of lower 
limb due 
to 
ischemia, 
cardiac 
sudden 
death; 
coronary 
revascular
“Concomita
nt drugs 
shall be 
recorded … 
shall also be 
recorded:  
1) Drugs for 
abnormal 
mineral 
metabolism 
and 
hyperparath
yroidism 2) 
Antihyperte
nsive drugs 
(calcium 
channel 
blocker, 
ACE 
inhibitor, 
Angiotensin 
receptor 
blocker, ß- 
blocker, α-
Informatio
n about 
other 
treatments 
in 
appendix  
 
Until the 
end of 
follow-
up 
 
No 
informatio
n on other 
cardiac 
preventive 
treatments 
(antihypert
ensives, 
antiplatelet
s, statins) 
48 
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ization 
and leg 
artery 
revascular
ization) 
blocker, 
loop 
diuretics, 
and others) 
3) Other 
cardiovascul
ar drugs (..) 
4) Anti-
platelet 
drugs (..) 5) 
Anti-
coagulants 
(..) 6) Anti-
diabetic 
drugs (…) 
7) Lipid-
lowering 
drugs 
(statin) 8) 
ESAs (…) 
9) Iron 
preparations 
(…)” 
2138831
0 
 
Irbesartan 
vs Placebo 
Patients 
with atrial 
fibrillation 
at risk for 
stroke 
Composite 
of stroke, 
MI, or 
death from 
vascular 
causes 
“Assessed 
at 
3,6,12,18,2
4 months. 
The 
incidence of 
the use of 
selected 
concomitant 
medications 
will be 
summarized 
in each 
treatment 
group” 
NI NI No 
informatio
n on other 
cardiac 
preventive 
treatments 
(statins) 
and 
anticoagul
ation in 
patients 
with atrial 
fibrillation  
49 
2884720
6 
 
Anacetrapi
b 
 vs 
Placebo 
Patients 
with CV 
disease 
and low 
HDL 
Composite 
of first 
major 
coronary 
event, a 
coronary 
death, MI, 
or 
coronary 
revascular
ization 
“Randomize
d 
participants 
who are 
receiving 
study 
atorvastatin 
at the lower 
doses and 
who, in the 
opinion of 
their 
managing 
doctors, 
require 
more 
intensive 
LDL-
lowering 
therapy may 
have the 
dose of 
atorvastatin 
increased 
(to a 
NI NI No 
informatio
n on other 
cardiac 
preventive 
treatments 
(antihypert
ensives, 
antiplatelet
s, statins) 
49
.2 
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maximum of 
20 mg daily 
in Far East, 
80 mg daily 
elsewhere).:
..” 
 
3041560
2 
Dapaglifloz
in vs 
Placebo 
Patients 
with type 
2 
diabetes 
and CV 
disease 
or at high 
CV risk 
Composite 
of CV 
death, MI, 
or 
ischemic 
stroke 
“All patients 
should be 
treated 
according to 
regional 
standards of 
care for CV 
risk factors 
(e.g., blood 
pressure, 
lipids, 
antithrombot
ic treatment) 
and HbA1c. 
Other 
medication(
s), which 
are 
considered 
necessary 
for the 
patient’s 
safety and 
well-being, 
may be 
given at the 
discretion of 
the 
Investigator” 
Informatio
n about 
other 
antidiabeti
cs across 
groups 
 
During 
follow-
up 
No 
informatio
n on other 
cardiac 
preventive 
treatments 
(antihypert
ensives, 
antiplatelet
s, statins) 
50
.4 
2577106
9 
 
Enalapril–
folic vs 
Enalapril 
alone 
Patients 
with 
hyperten
sion 
Stroke “Any drugs 
other than 
use of folic 
acid are 
permitted.   
Proper 
control of 
blood 
pressure 
should be 
used as a 
goal for anti-
hypertensiv
e  
medications 
other than 
the study 
drugs.   
…  If blood 
pressure is 
not properly 
controlled, 
other anti-
hypertensiv
e 
medications 
can be  
NI 
Info about 
other 
antihypert
ensives in 
text not 
across 
groups 
 
NI No 
informatio
n on other 
cardiac 
preventive 
treatments 
(antiplatele
ts, statins) 
54 
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added 
based on 
the 
recommend
ation of the 
“Chinese 
Guidelines 
of 
Hypertensio
n  
Managemen
t” published 
in 2005. 
Controlling 
of the blood 
pressure 
within a 
normal 
range  
is not 
mandatory.  
The first 
choices of 
anti-
hypertensiv
e drugs to 
be added 
are..” 
2449026
4 
 
High-dose 
multivitami
n vs 
Placebo 
Patients 
with prior 
MI 
Composite 
of total 
death, 
recurrent 
MI, stroke, 
coronary 
revascular
ization, or 
hospitalisa
tion for 
angina 
NI NI NI No 
informatio
n on other 
cardiac 
preventive 
treatments 
(antihypert
ensives, 
antiplatelet
s, statins) 
55 
2353224
0 
 
EDTA 
Chelation 
solution vs 
Placebo 
Patients 
with prior 
MI 
Composite 
of total 
mortality, 
recurrent 
MI, stroke, 
coronary 
revascular
ization, or 
hospitalisa
tion for 
angina 
 
NI NI NI No 
informatio
n on other 
cardiac 
preventive 
treatments 
(antihypert
ensives, 
antiplatelet
s, statins) 
55 
3041562
8 
Icosapent 
Ethyl vs 
Placebo 
Patients 
with CV 
disease 
or with 
diabetes 
and other 
risk 
factors 
Composite 
of CV 
death, 
nonfatal 
MI, 
nonfatal 
stroke, 
coronary 
revascular
ization, or 
“Any 
medications 
administere
d during the 
study period 
must be 
documented 
on the 
Concomitan
t Medication 
CRF. ..The 
NI NI No 
informatio
n on other 
cardiac 
preventive 
treatments 
(antihypert
ensives, 
antiplatelet
s) and 
hypoglyce
56
.5 
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unstable 
angina 
following 
products are 
allowed: 
statins, 
ezetimibe, 
and herbal 
products & 
dietary 
supplement
s not 
containing 
omega-3 
fatty acids” 
mic 
medication
s 
2688641
8 
Pioglitazon
e vs 
Placebo 
Patients 
with 
recent 
ischemic 
stroke or 
TIA 
Composite 
of fatal or 
non-fatal 
stroke, MI 
D.8.2 
Definition 
and 
Managemen
t of Vascular 
Risk Factors 
D.8.2.1 
Hypertensio
n 
D.8.2.2 
Elevated 
Blood Lipids 
D.8.2.3 
Carotid 
Artery 
Disease 
D.8.2.4 
Atrial 
Fibrillation 
D.8.2.5 
Cigarette 
Smoking  
D.8.2.6 Diet, 
Exercise, 
and Weight  
D.8.3  Other 
Preventive 
Therapy 
Statins, 
“on blood 
pressure 
goal”, 
anticoagul
ants or 
antiplatele
ts, 
hypoglyce
mic 
medicatio
ns, 
smoking 
 
Each 
year 
unti end 
of 
follow-
up 
 
- 57
.6 
2166394
9 
 
Simvastati
n plus 
Ezetimibe 
vs Placebo 
Patients 
with 
chronic 
kidney 
disease 
MACE 
(non-fatal 
MI or 
coronary 
death, 
non-
hemorrha
gic stroke, 
or any 
arterial 
revascular
ization 
procedure
) 
From 
published 
study 
design: NI 
NI NI No 
informatio
n on other 
cardiac 
preventive 
treatments 
(antihypert
ensives, 
antiplatelet
s) 
58
.8 
3015806
9 
Aspirin vs 
Placebo 
Patients 
with 
moderate 
CV risk 
Composite 
outcome 
of time to 
first 
occurrenc
e of CV 
death, MI, 
No protocol  NI NI No 
informatio
n on other 
cardiac 
preventive 
treatments 
(antihypert
60 
D
ow
nloaded from
 http://ahajournals.org by on June 17, 2020
 
 
unstable 
angina, 
stroke, or 
TIA 
ensives, 
statins) 
2365664
5 
 
N-3 fatty 
acids vs 
Placebo 
Patients 
with 
multiple 
CV risk 
factors or 
atheroscl
erotic 
vascular 
disease 
but not 
MI 
Composite 
of CV 
death or 
admission 
to the 
hospital 
for CV 
causes 
(revised) 
“3.2 Terapie 
concomitant
i  
Nonostante 
i molteplici 
effetti 
farmacologi
ci degli n-3 
PUFA, al 
dosaggio 
utilizzato 
nello studio, 
non sono 
note 
interazioni 
clinicamente 
rilevanti con 
i principali 
farmaci 
cardiovascol
ari compresi 
antiaggrega
nti, 
anticoagula
nti e 
antiaritmici” 
ACEI/ARB
s, statins, 
antiplatele
ts 
 
At the 
end of 
follow-
up 
 
- 60 
2540132
5 
Aspirin vs 
Control 
Patients 
with 
hyperten
sion, 
dyslipide
mia, or 
type 2 
diabetes  
Composite 
of death 
from CV 
causes 
(MI, 
stroke, 
and other 
CV 
causes), 
nonfatal 
stroke 
(ischemic 
or 
hemorrha
gic, 
including 
undefined 
cerebrova
scular 
events), 
and 
nonfatal 
MI 
“Treatment 
to control 
hypertensio
n, 
dyslipidemia
, or diabetes 
(ie, the 
underlying 
risk factors 
for vascular 
events) was 
administere
d to all 
eligible 
patients at 
the 
screening 
visit and, in 
principle, 
throughout 
the study, in 
accordance 
with 
Japanese 
therapeutic 
guideline” 
(no 
protocol) 
NI NI No 
informatio
n on other 
cardiac 
preventive 
treatments 
(antihypert
ensives, 
statins) 
60
.2 
2312137
4 
Cinacalcet 
vs Placebo 
Patients 
with 
chronic 
Composite 
of death, 
MI, 
hospitalisa
“Concomita
nt therapy 
will be 
collected 
“The 
provision 
of 
antiplatele
During 
follow-
up 
- 64 
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kidney 
disease 
tion for 
unstable 
angina, 
HF, or a 
peripheral 
vascular 
event 
from day 1 
through the 
end of the 
study” 
t agents, 
statins, 
beta-
blockers, 
and 
inhibitors 
of the 
renin–
angiotensi
n–
aldosteron
e system 
did not 
materially 
change 
over time 
in either 
group” 
(text) 
 
2632393
7 
Benznidaz
ole vs 
Placebo 
Patients 
with 
establish
ed 
Chagas' 
cardiomy
opathy 
Composite 
of death, 
resuscitat
ed cardiac 
arrest, 
sustained 
ventricular 
tachycardi
a, 
insertion 
of a 
pacemake
r or 
implantabl
e 
cardiovert
er-
defibrillato
r, cardiac 
transplant
ation, new 
HF, 
stroke, or 
other 
thromboe
mbolic 
event 
“Any 
concomitant 
therapy, 
including 
treatments 
demonstrate
d to be 
effective in 
the study 
population 
is permitted” 
NI NI No 
informatio
n on other 
cardiac 
preventive 
treatments 
(antihypert
ensives, 
antiplatelet
s, statins), 
diuretics, 
aldosteron
e receptor 
inhibitors 
64
.8 
2704148
0 
Candesart
an/HCT vs 
Placebo 
Patients 
with 
intermedi
ate  CV 
risk  
Composite 
of CV 
death, 
nonfatal 
MI, 
nonfatal 
stroke 
 
“Concomita
nt 
treatments 
assessed 0, 
24, end of 
FU; 
Concurrent 
Treatments: 
There are 
no other 
restrictions 
to the use of 
additional 
therapies. If 
clinicians 
managing 
Only 
informatio
n about 
other 
antihypert
ensives in 
table 
across 
groups 
 
At 2 
years 
and at 
the end 
of 
follow-
up 
 
No 
informatio
n on other 
cardiac 
preventive 
treatments 
(antiplatele
ts) 
67
.2 
D
ow
nloaded from
 http://ahajournals.org by on June 17, 2020
 
 
individual 
study 
participants 
believe that 
lipid 
modifying or 
blood 
pressure 
lowering 
treatments 
are clinically 
indicated 
after 
randomizati
on, open 
label lipid 
modifying or 
blood 
pressure 
lowering 
drug(s) can 
be added. 
Whenever 
possible, 
drugs other 
than statins, 
ARBs, ACE 
inhibitors 
and thiazide 
diuretics 
should be 
used..” 
 
2703994
5 
 
Rosuvastat
in and 
Candesart
an/HCT vs 
Placebo 
Patients 
with 
intermedi
ate  CV 
risk 
Composite 
of CV 
death, 
nonfatal 
MI, or 
nonfatal 
stroke 
“Concomita
nt 
treatments 
assessed 0, 
24, end of 
FU; 
Concurrent 
Treatments: 
There are 
no other 
restrictions 
to the use of 
additional 
therapies. If 
clinicians 
managing 
individual 
study 
participants 
believe that 
lipid 
modifying or 
blood 
pressure 
lowering 
treatments 
are clinically 
indicated 
after 
randomizati
NI NI No 
informatio
n on other 
cardiac 
preventive 
treatments 
(antiplatele
ts) 
67
.2 
D
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on, open 
label lipid 
modifying or 
blood 
pressure 
lowering 
drug(s) can 
be added. 
Whenever 
possible, 
drugs other 
than statins, 
ARBs, ACE 
inhibitors 
and thiazide 
diuretics 
should be 
used..” 
 
2704013
2 
 
Rosuvastat
in vs 
Placebo 
Patients 
with 
intermedi
ate CV 
risk 
Composite 
of CV 
death, 
nonfatal 
MI, or 
nonfatal 
stroke 
“Concomita
nt 
treatments 
assessed 0, 
24, end of 
FU; 
Concurrent 
Treatments: 
There are 
no other 
restrictions 
to the use of 
additional 
therapies. If 
clinicians 
managing 
individual 
study 
participants 
believe that 
lipid 
modifying or 
blood 
pressure 
lowering 
treatments 
are clinically 
indicated 
after 
randomizati
on, open 
label lipid 
modifying or 
blood 
pressure 
lowering 
drug(s) can 
be added. 
Whenever 
possible, 
drugs other 
than statins, 
ARBs, ACE 
inhibitors 
NI NI No 
informatio
n on other 
cardiac 
preventive 
treatments 
(antiplatele
ts) 
67
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and thiazide 
diuretics 
should be 
used..” 
 
2603952
1 
 
Simvastati
n plus 
Ezetimibe 
vs 
Simvastati
n plus 
Placebo 
Patients 
with 
recent 
ACS 
Composite 
of CV 
death, 
nonfatal 
MI, 
unstable 
angina 
requiring 
rehospitali
sation, 
coronary 
revascular
ization or 
nonfatal 
stroke 
“CV 
Concomitan
t 
Medications 
Review in 
each visit. 
The use of 
any 
concomitant 
medication 
must relate 
to an 
adverse 
event or the 
subject's 
medical 
history” 
NI NI No 
informatio
n on other 
cardiac 
preventive 
treatments 
(antihypert
ensives, 
antiplatelet
s) 
72 
2268641
5 
N-3 fatty 
acids vs 
Placebo 
Patients 
at  for CV 
risk  and 
impaired 
fasting 
glucose, 
impaired 
glucose 
tolerance
, or 
diabetes 
Composite 
of death 
from 
coronary 
heart 
disease, 
nonfatal 
MI, 
ischemic 
stroke, 
hospitalisa
tion for an 
acute 
coronary 
syndrome, 
or 
symptom-
driven 
coronary 
or cerebral 
revascular
ization 
“Concomita
nt 
medications 
may be 
used at the 
discretion of 
the 
participant’s 
physician 
when 
indicated for 
the 
participant’s 
welfare. 
Participants 
will be 
formally 
asked about 
the types of 
concomitant 
treatments 
every year.  
As noted 
above, 
TZDs will 
not be 
permitted in 
combination 
with insulin 
glargine” 
NI NI No 
informatio
n on other 
cardiac 
preventive 
treatments 
(antihypert
ensives, 
antiplatelet
s, statins) 
and 
hypoglyce
mic 
medication
s 
74
.4 
2268641
6 
Insulin-
glargine vs 
standard-
care 
Patients 
with CV 
risk 
factors 
plus 
impaired 
fasting 
glucose, 
impaired 
glucose 
Composite 
of nonfatal 
MI, 
nonfatal 
stroke, or 
CV death 
“Concomita
nt 
medications 
may be 
used at the 
discretion of 
the 
participant’s 
physician 
when 
Lipid 
lowering, 
antihypert
ensives 
(Thiazid, 
ACEI/ARB
s, b-
blocker, 
other), 
antiplatele
At the 
end of 
follow-
up 
 
- 74
.4 
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tolerance
, or type 
2 
diabetes 
indicated for 
the 
participant’s 
welfare.  
Participants 
will be 
formally 
asked about 
the types of 
concomitant 
treatments 
every year.  
As noted 
above, 
TZDs will 
not be 
permitted in 
combination 
with insulin 
glargine” 
ts, other 
antidiabeti
cs 
 
3014693
2 
N-3 fatty 
acids vs 
Placebo 
Patients 
with type 
2 
diabetes 
Composite 
of serious 
vascular 
event (i.e., 
nonfatal 
MI or 
stroke, 
transient 
ischemic 
attack, or 
vascular 
death) 
“Follow-up 
questionnair
es asking 
about use of 
relevant 
non-study 
treatments 
will be sent 
6-monthly 
with a 
further 
supply of 
the 
participant’s 
allocated 
study 
treatment” 
Statins, 
ACEI/ARB
s, 
hypoglyce
mic 
medicatio
ns, b-
blockers, 
calcium 
channel 
blockers, 
diuretics 
(antiplatel
ets part of 
2x2 
factorial) 
 
At the 
end of 
follow-
up 
 
- 88
.8 
3014693
1 
Aspirin vs 
Placebo 
Patients 
with type 
2 
diabetes 
Composite 
of serious 
vascular 
event (i.e., 
nonfatal 
myocardia
l infarction 
or stroke, 
transient 
ischemic 
attack, or 
vascular 
death) 
“Follow-up 
questionnair
es asking 
about use of 
relevant 
non-study 
treatments 
will be sent 
6-monthly 
with a 
further 
supply of 
the 
participant’s 
allocated 
study 
treatment” 
Statins, 
ACEI/ARB
s, 
hypoglyce
mic 
medicatio
ns, b-
blockers, 
calcium 
channel 
blockers, 
diuretics 
 
At the 
end of 
follow-
up 
- 88
.8 
3004306
5 
 
Escitalopra
m vs 
Placebo 
Patient 
with 
recent 
ACS and 
depressio
n 
Composite 
of all-
cause 
mortality, 
MI, and 
percutane
ous 
coronary 
“Any 
change in 
concomitant 
medications 
or dosage 
will be 
documented
NI NI No 
informatio
n on other 
cardiac 
preventive 
treatments 
(antihypert
ensives, 
97
.2 
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interventio
n 
. Allowed 
drugs: …” 
antiplatelet
s, statins) 
2311777
5 
 
Multivitami
n vs 
Placebo 
Male 
physician
s; 
subgroup 
with CV 
disease 
Composite 
of MACE, 
including 
nonfatal 
MI, 
nonfatal 
stroke, 
and CVD 
mortality. 
From 
published 
study 
design: “We 
will use the 
Cox 
proportional 
hazards 
model to 
compare 
event rates 
for each 
treatment 
group while 
controlling 
simultaneou
sly for 
variable 
lengths of 
follow-up, 
other 
treatment 
assignment
s, and any 
risk factors 
that are 
unbalanced” 
NI NI No 
informatio
n on other 
cardiac 
preventive 
treatments 
(antihypert
ensives, 
antiplatelet
s, statins) 
13
4 
Long 
term 
follow-
up (>1 
month) 
with 
index 
procedu
re after 
randomi
zation 
 
        
2704308
2 
 
Losmapim
od vs 
Placebo 
Patients 
with ACS 
Composite 
of CV 
death, MI, 
or severe 
recurrent 
ischemia 
requiring 
urgent 
coronary 
revascular
ization 
“Investigator
s will 
manage the 
subjects 
according to 
standard of 
care, 
following 
local 
prescribing 
information. 
Close 
adherence 
to 
professional 
society 
guidelines 
for standard 
of care 
therapies in 
ACS will be 
Aspirin, 
P2Y12 
inhibitors, 
statin, b 
blocker, 
ACE/ARB
s 
At 
discharg
e 
No 
informatio
n on 
procedural 
characteris
tics 
5.
5 
D
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emphasized 
during study 
conduct, 
including 
anti-platelet 
therapy, 
statin 
medications
, use of 
appropriate 
revasculariz
ation, ACEIs 
and b-
blockers. All 
concomitant 
medications 
taken during 
the study 
will be 
recorded in 
the eCRF” 
2884420
1 
 
Bivalirudin 
vs Heparin 
Patients 
with ACS 
undergoi
ng PCI 
Composite 
of death 
from any 
cause, MI, 
or major 
bleeding 
“Procedure 
strategies: 
All other 
treatments. 
are 
according to 
local 
tradition. 
GpIIb/IIIa 
inhibitors 
may be 
given as 
bailout 
treatment 
according to 
physician´s 
decision. 
After the 
index PCI, 
lifelong 
acetylsalicyli
c acid .. will 
be 
prescribed” 
 
Periproce
dural 
characteri
stics; 
aspirin, 
clopidogre
l, 
GpIIb/IIIa 
inhibitors, 
b-
blockers, 
statins, 
ACEI/ARB
s, calcium 
channel 
blockers, 
anticoagul
ants 
Periproc
edural & 
at 
discharg
e 
Type of 
stent is not 
reported 
5.
9 
2417725
7 
 
3 months 
vs 12 
months of 
dual 
treatment 
Patients 
undergoi
ng PCI 
with 
zotarolim
us-eluting 
stents 
Net 
adverse 
clinical 
and 
cerebral 
events 
(MACE 
and major 
bleeding) 
“All 
intervention
s were 
recommend
ed to be 
performed 
according to 
the current 
standard 
guidelines, 
and final 
procedure 
strategy 
was left 
entirely at 
the 
operators’ 
Informatio
n about 
procedural 
characteri
stics  
Periproc
edural 
Access 
site per 
group is 
missing. 
Periproced
ural 
medication
s missing; 
Informatio
n o other 
cardiac 
preventive 
treatments 
(antihypert
ensives, 
statins) at 
end of 
12 
D
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discretion. 
Direct 
stenting and 
implant of 
multiple E-
ZES were 
allowed” 
(from 
published 
study 
design) 
follow-up 
missing 
2207781
6 
 
Vorapaxar 
vs Placebo 
Patients 
with 
NSTEMI 
Composite 
of CV 
death, MI, 
stroke, 
recurrent 
ischemia 
with 
rehospitali
sation, or 
urgent 
coronary 
revascular
ization 
“In general, 
record in the 
eCRF those 
medications 
or therapies 
taken, used, 
or 
administere
d during the 
study..” 
Only 
informatio
n about 
procedural 
characteri
stics  
Periproc
edural 
No 
informatio
n on other 
cardiac 
preventive 
treatments 
(antihypert
ensives, 
antiplatelet
s, statins) 
16
.5 
2954469
9 
6 vs 12 
months of 
of dual 
treatment 
(Clopidorg
el and 
Aspirin) 
Patients 
with ACS 
undergoi
ng PCI 
with 
drug-
eluting 
stents 
Composite 
of all-
cause 
death, MI, 
or stroke 
“Direct 
stenting or 
prediltion 
and 
antithrombot
ic 
medications 
during the 
procedure, 
and use of 
glycoprotein 
IIb/IIIa 
inhibitors 
will be up to 
operatos 
discretion. 
The length 
and 
diameter of 
the stent will 
not be 
restricted” 
(from 
published 
study 
design) 
Informatio
n about 
procedural 
characteri
stics & 
medicatio
ns; 
heparin, 
GpIIb/IIIa 
inhibitors 
and 
discharge 
medicatio
ns: 
aspirin, 
clopidogre
l, b-
blockers, 
statins, 
ACEI/ARB
s, 
 
Periproc
edural & 
at 
discharg
e 
No 
informatio
n on other 
cardiac 
preventive 
treatments 
(antihypert
ensives, 
statins) at 
the end of 
follow-up; 
no 
informatio
n for 
balloon 
dilatation 
 
18 
3016607
3 
Aspirin and 
Tigagrelor 
vs 
Aspirin and 
Clopidogrel 
Patients 
undergoi
ng 
elective 
or urgent 
PCI with 
drug-
eluting 
stents 
Composite 
of all-
cause 
mortality 
or non-
fatal  new 
Q-wave 
MI 
“Balloon 
angioplasty 
and stent 
implantation 
were 
performed 
according to 
standard 
techniques; 
direct 
stenting 
(without 
Informatio
n about 
procedural 
characteri
stics 
Periproc
edural 
No 
informatio
n on other 
cardiac 
preventive 
treatments 
(antihypert
ensives, 
antiplatelet
s, statins)  
24 
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previous 
balloon 
dilatation) 
was 
allowed. 
Staged 
procedures 
were 
permitted ... 
Glycoprotei
n IIB/IIIA 
receptor 
inhibitors 
were to be 
administere
d only in 
patients 
who had 
periprocedu
ral ischemic 
complication
s (i.e., no 
reflow or 
giant 
thrombus) 
after 
stenting. 
The use of 
unfractionat
ed heparin 
(up to an 
arbitrary set 
maximum of 
4000IU) 
during the 
index 
diagnostic 
angiogram 
was left at 
the 
discretion of 
the 
investigator. 
The use of 
other 
medications 
was per 
applicable 
professional 
guidelines” 
2632110
3 
 
Cyclospori
n vs 
Placebo 
Patients 
with 
STEMI 
undergoi
ng PCI 
(randomi
zation 
before 
recanaliz
ation) 
Composite 
of death 
from any 
cause, 
worsening 
of HF 
during the 
initial 
hospitalisa
tion, 
rehospitali
sation for 
HF, or 
“Associated 
treatments 
(anti-
platelets 
agents, 
anticoagula
nts, ACE-I, -
blockers, 
statins, n-3 
PUFA …) 
will be 
administere
d according 
Procedura
l 
characteri
stics and 
periproced
ural 
medicatio
ns; lipid 
lowering, 
antihypert
ensives, 
anticoagul
ants, 
Periproc
edural & 
at 
discharg
e 
No 
informatio
n on 
cardiac 
preventive 
treatments 
(antihypert
ensives, 
antiplatelet
s, statins) 
at end of 
follow-up; 
Type of 
12 
D
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adverse 
left 
ventricular 
remodelin
g at 1 year 
to the 
current 
guidelines 
..”; 
“Coronary 
angioplasty 
and stenting 
will be 
performed 
according to 
the usual 
procedures 
utilized by 
the 
cardiologist 
in 
charge….” 
antidiabeti
cs 
stent is 
missing 
Short 
term 
follow-
up (<1 
month) 
with 
index 
procedu
re after 
randomi
zation 
 
        
2347336
9 
 
Cangrelor 
vs 
Clopidogrel 
Patients 
undergoi
ng urgent 
or 
elective 
PCI 
Composite 
of death, 
MI, 
ischemia-
driven 
revascular
ization or 
stent 
thrombosi
s 
“All patients 
should 
receive 
standard of 
care 
antiplatelet 
therapy per 
ACC/AHA/E
SC 
guidelines; 
The 
following 
allowed 
medications 
may 
constitute 
standard 
care and will 
be allowed 
as 
concomitant 
medications
, 
including…. 
institution‘s 
standard 
practices 
during the 
index PCI 
procedure 
with the 
exception of 
medications 
prohibited 
Procedura
l 
characteri
stics and 
periproced
ural 
medicatio
ns (P2Y12 
inhibitors 
use, 
bivalirudin
, heparin, 
fondaparin
ux, 
aspirin) 
Periproc
edural & 
at 
discharg
e 
- 0.
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under this 
protocol” 
2399560
8 
 
Otamixaba
n vs 
Heparin 
plus 
eptifibatide 
Patients 
with 
NSTEMI 
undergoi
ng PCI 
Composite 
of all-
cause 
death or 
new MI 
“In addition 
to study 
medication, 
all 
randomized 
patients 
must 
receive both 
aspirin and 
an oral 
adenosine 
diphosphate 
receptor 
antagonist 
given as per 
their local 
label or 
international 
guidelines.  
Both radial 
and femoral 
access for 
angiography 
and PCI are 
allowed. For 
patients 
having 
femoral 
access, if a 
closure 
device is 
used, the 
sheath …..” 
Procedura
l 
characteri
stics and 
periproced
ural 
medicatio
ns (P2Y12 
inhibitors 
use, 
bivalirudin
, heparin, 
fondaparin
ux, 
aspirin) 
and 
aspirin, 
clopidogre
l, Gp 
IIb/IIIAa 
inhibitors, 
b-
blockers, 
statins, 
ACEI/ARB
s 
Periproc
edural & 
at 
discharg
e 
Type of 
stent not 
reported, 
balloon-
dilatation 
not 
reported 
0.
23 
2500217
8 
 
Bivalirudin 
vs Heparin 
Patients 
undergoi
ng 
primary 
PCI 
Composite 
of all-
cause 
mortality, 
cerebrova
scular 
accident, 
reinfarctio
n, or 
unplanned 
target 
lesion 
revascular
isation 
“The GP 
IIb/IIIa 
inhibitor, 
abciximab, 
was allowed 
for selective 
use in both 
groups as 
per the 
European 
Society of 
Cardiology 
guidelines 
(..). No 
other trial-
related 
restrictions 
were 
imposed on 
the 
performanc
e of 
angiography 
and PCI, 
which were 
done in 
accordance 
with 
ACEI/ARB
s, aspirin, 
clopidogre
l, statin at 
discharge 
and 
procedural 
characteri
stics and 
periproced
ural 
medicatio
ns 
(Aspirin, 
P2Y12-
inhibitor 
loading 
dose, 
GpIIb/IIIa)  
 
Periproc
edural & 
at 
discharg
e 
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prevailing 
best local 
practice as 
determined 
by the 
attending 
intervention
al 
cardiologist” 
 (no 
protocol) 
2467906
2 
 
Aspirin vs 
Placebo 
Patients 
undergoi
ng 
noncardi
ac 
surgery 
Composite 
of death or 
nonfatal 
MI 
“All aspects 
of the 
patient’s 
managemen
t are at the 
discretion of 
the 
attending 
physician.  
This 
includes all 
decisions on 
antiplatelet, 
anticoagulat
ion, and 
anti-
ischemic 
therapies.  
We will 
encourage 
physicians 
not to 
prescribe an 
alpha-2 
agonist …. 
We will also 
encourage 
physicians 
not to 
prescribe 
antiplatelet 
therapy 
during the 
initial 7 days 
after 
surgery ….”  
Anticoagul
ants, 
NSAID, 
statin, 
Cox-2, b-
blocker, 
P2Y12, 
perioperati
ve 
antifibrinol
ytic & 
procedural 
characteri
stics 
During 
the first 
3 days 
 
- 1 
2467906
1 
 
Clonidine 
vs Placebo 
Patients 
undergoi
ng 
noncardi
ac 
surgery 
Composite 
of death or 
nonfatal 
MI 
“All aspects 
of the 
patient’s 
managemen
t are at the 
discretion of 
the 
attending 
physician.  
This 
includes all 
decisions on 
antiplatelet, 
anticoagulat
ion, and 
anti-
B-blocker, 
Calcium-
Channel 
blockers, 
statin, a2-
adrenergiv 
agonist & 
procedural 
characteri
stics 
(antiplatel
ets as part 
of factorial 
2x2) 
During 
the first 
3 days 
 
- 1 
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ischemic 
therapies.  
We will 
encourage 
physicians 
not to 
prescribe an 
alpha-2 
agonist …. 
We will also 
encourage 
physicians 
not to 
prescribe 
antiplatelet 
therapy 
during the 
initial 7 days 
after 
surgery ….”  
2759021
8 
 
Edoxaban 
vs 
Enoxaparin
–warfarin 
Patients 
undergoi
ng 
cardiover
sion for 
atrial 
fibrillation 
Composite 
of stroke, 
systemic 
embolic 
event, MI, 
CV death 
“There are 
no 
concomitant 
medications 
required as 
part of the 
study 
design.  
The study 
procedures 
detailed 
below are 
for both 
TEE and 
non-TEE-
guided 
subjects, 
unless 
specifically 
stated 
otherwise. 
As much as 
possible, 
procedures 
must be 
followed 
in the order 
listed” 
NI 
 
- No 
informatio
n on 
antiplatelet
s, or 
procedural 
characteris
tics 
1 
2311777
6 
 
Dexameth
asone vs 
Placebo 
Patients 
undergoi
ng 
cardiac 
surgery 
Composite 
of death, 
MI, stroke, 
renal 
failure, or 
respiratory 
failure 
“Anesthesia 
and surgical 
treatment 
were 
performed 
according to 
the standard 
procedures 
of each 
participating 
center”. (no 
protocol) 
B-
blockers, 
statin, 
corticoster
oid & 
procedural 
characteri
stics 
 
Periproc
edural 
 
No 
informatio
n on 
antiplatelet
s 
1 
2577505
2 
Bivalirudin 
vs Heparin 
Patients 
undergoi
Composite 
of MACE 
“Anticoagula
nt agent 
ACEI/ARB
s, aspirin, 
Periproc
edural & 
- 1 
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 vs Heparin 
plus 
Tirofiban 
ng 
primary 
PCI 
or cerebral 
events 
(all-cause 
death, 
reinfarctio
n, 
ischemia-
driven 
target 
vessel 
revascular
ization, or 
stroke) or 
bleeding 
(heparin, 
LMWH, etc.) 
post 
procedure is 
not 
recommend
ed 
Provisional 
(bailout) 
tirofiban use 
is allowed in 
the 
bivalirudin 
and heparin 
alone arms 
for no-
reflow, slow 
flow, visible 
thrombus or 
other 
thrombotic 
complication
” 
clopidogre
l, statin 
and 
procedural 
characteri
stics and 
periproced
ural 
medicatio
ns 
(aspirin, 
P2Y12-
inhibitor 
loading 
dose, 
GpIIb/IIIa 
inhibitors) 
at 
discharg
e  
2207790
9 
 
Abciximab 
plus 
Heparin vs 
Bivalirudin 
Patients 
with 
NSTEMI 
undergoi
ng PCI 
Composite 
of death, 
large 
recurrent 
MI, urgent 
target-
sessel 
revascular
isation, 
major 
bleeding 
“Concomita
nt 
medication 
assessed at 
discharge. 
Post-
intervention
ally Sheath 
should … 
respectively. 
After the 
intervention, 
all patients 
will receive 
80-325 
mg/day 
aspirin 
indefinitely, 
clopidogrel 
75-150 mg 
until 
discharge 
(but no 
longer than 
3 days) 
followed by 
at least 75 
mg/day for 
at least 6 
months and 
other 
cardiac 
medications 
according to 
the 
judgment of 
patient’s 
physician 
(e.g. ß-
blockers, 
Procedura
l 
characteri
stics and 
periproced
ural 
medicatio
ns 
(GpIIb/IIIa 
inhibitors, 
bivalirudin
, heparin, 
randomiza
tion after 
aspirin & 
P2Y12 
was 
given) 
Periproc
edural  
 
- 1 
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ACE-
inhibitors, 
statins etc)” 
2185648
3 
 
Enoxaparin 
vs Heparin 
Patients 
with 
STEMI 
undergoi
ng PCI 
Composite 
of death, 
complicati
on of MI, 
procedure 
failure, or 
major 
bleeding 
Procedures 
described in 
paper (no 
protocol) 
Aspirin, 
clopidogre
l, Gp 
IIb/IIIa 
inhibitors,
statins, b 
blocker, 
ACEI/ARB
S 
periproced
ural and 
periproced
ural 
characteri
stics 
Periproc
edural  
 
- 1 
2245280
7 
 
Glucose-
insulin-
potassium 
vs Placebo 
Patients 
with 
suspecte
d ACS 
MI 
 
NI 
(published 
study 
design) 
NI - No 
informatio
n on 
medication
s 
(anticoagul
ants, 
antiplatelet
s) or 
procedural 
characteris
tics 
1 
2417149
0 
 
Bivalirudin 
vs Heparin 
Patients 
with 
STEMI 
undergoi
ng PCI 
Composite 
of death or 
major 
bleeding 
not 
associated 
with 
coronary-
artery 
bypass 
grafting 
“Once a 
patient has 
commenced 
treatment 
with an anti-
thrombin (..) 
no change 
in strategy 
is 
recommend
ed. In 
patients 
requiring 
ongoing 
anti-
coagulation 
for reasons 
other than 
PCI then 
anticoagulat
ion should 
be 
maintained 
as per local 
practice.  
Glycoprotei
n IIb/IIIa 
Inhibitor 
Managemen
t: In patients 
randomised 
to the 
Aspirin, 
clopidogre
l, b-
blockers, 
statins, 
ACEI/ARB
s at 
discharge 
and 
procedural 
characteri
stics and 
periproced
ural 
medicatio
ns 
(aspirin, 
P2Y12-
inhibitor 
loading 
dose, 
heparin, 
bivalirubin
, 
enoxapari
n), 
GpIIb/IIIa 
inhibitors) 
Periproc
edural & 
at 
discharg
e 
- 1 
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control arm 
the use of a 
GPI will be 
classified as 
either 
“routine” 
(treatment 
of patients 
before or 
during 
angiography 
but not once 
PCI has 
commenced
) or “bail 
out” 
(treatment 
of patients 
during or 
after PCI)” 
2632404
9 
 
Bivalirudin 
vs Heparin 
Patients 
with ACS 
undergoi
ng PCI 
Composite 
of urgent 
target-
vessel 
revascular
ization, 
definite 
stent 
thrombosi
s, or net 
adverse 
clinical 
events 
Only 
information 
on vascular 
access site: 
transfemoral 
access 
Procedura
l 
characteri
stics; 
Periproce
dural 
medicatio
ns and 
medicatio
ns at 
discharge 
(aspirin, 
clopidogre
l, 
GpIIb/IIIA
a 
inhibitors, 
b-
blockers, 
statins, 
ACEI/ARB
s, 
diuretics, 
antidiabeti
cs) 
Periproc
edural & 
at 
discharg
e 
Type of 
stent 
missing 
1 
2952582
1 
Atorvastati
n vs 
Placebo 
Patients 
with ACS 
undergoi
ng PCI 
Composite 
of all-
cause 
mortality, 
MI, stroke, 
and 
unplanned 
coronary 
revascular
ization 
“Co-
intervention
s: 
Concomitan
t treatment 
with ASA 
and 
clopidogrel 
will be 
recommend
ed for all 
patients at 
discharge. 
Due to its 
pragmatic 
design, the 
co-
intervention
Procedura
l 
characteri
stics, 
periproced
ural 
medicatio
ns: only 
heparin 
Periproc
edural 
Procedural 
characteris
tics: 
Access 
site is 
missing. 
Medication
s: No 
informatio
n on 
GIIb/IIIa, 
unclear if 
aspirin, 
clopidogrel
, b-
blockers, 
ACEIs/AR
Bs on 
1 
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s choice will 
be at the 
medical 
staff 
discretion.   
Nevertheles
s, the use of 
the following 
agents 
listed below 
will be 
strongly 
recommend
ed to all  
sites 
(except if 
contraindica
tions are 
present). 
The 
percutaneo
us coronary 
intervention 
will be 
performed 
according to 
the current 
clinical  
practice of 
the 
Institution, 
using either 
the 
transfemoral 
or the 
transradial 
access. 
Stents   
implantation
, as well as 
stent 
characteristi
cs, will be at 
the 
intervention
al 
cardiologist 
discretion” 
baseline 
table are 
before 
admission 
or 
periproced
ural 
2609586
7 
Low 
Molecular 
Weight 
Heparin vs 
Placebo 
Patients 
with atrial 
fibrillation 
undergoi
ng 
surgery 
Arterial 
thromboe
mbolism 
(stroke, 
systemic 
embolism, 
TIA) 
Potential co-
Intervention
s: 
information 
on other 
concomitant 
antiplatelet 
Therapy, 
antithrombot
ic drugs 
Aspirin, 
clopidogre
l, NSAIDs, 
Cox-2, 
heparin, 
warfarin & 
procedural 
characteri
stics 
Periproc
edural 
 
- 1 
2399162
2 
Prasugrel 
vs Placebo 
Patients 
with 
NSTEMI 
undergoi
ng PCI 
Composite 
of CV 
death, MI, 
stroke, 
urgent 
Only 
information 
in the use of 
other 
antiplatelets 
Procedura
l 
characteri
stic; 
periproced
Periproc
edural 
 
Procedural 
characteris
tics: Stent 
type is 
missing 
1 
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revascular
ization, or 
glycoprote
in IIb/IIIa 
inhibitor 
rescue 
therapy 
(Gp IIbIIIa 
bailout) 
drugs in 
protocol    
ural 
medicatio
ns: 
heparin, 
bivalirudin
, 
fondaparin
ux, 
aspirin, 
clopidogre
l, PPI, b-
Blocker, 
statin, 
ACEI/ 
ARBs, 
clopidogre
l, calcium 
channel 
blockers 
2693384
8 
 
Aspirin vs 
Placebo 
Patients 
undergoi
ng 
cardiac 
surgery 
Composite 
of death 
and 
thrombotic 
complicati
ons 
(nonfatal 
MI, stroke, 
pulmonary 
embolism, 
renal 
failure, or 
bowel 
infarction) 
“All other 
perioperativ
e clinical 
care will be 
according to 
standard 
practice as 
this is an 
effectivenes
s trial and 
some 
elements of 
the trial are 
deliberately 
left to the 
clinicians’ 
discretion in 
order to 
reflect usual 
practice and 
maximise 
generalisabi
lity.  
Anaesthesia 
and surgery 
will be 
according to 
local 
practices…. 
All such 
relevant 
perioperativ
e data will 
be recorded 
on the CRF”  
ACEI/ARB
s, aspirin, 
clopidogre
l, statin, b-
blocker, 
diuretics, 
digoxin, 
NSAID, 
amiodaron
e, and 
procedural 
characteri
stics 
Periproc
edural & 
up to 7 
days 
 
- 1 
2777483
8 
 
Tranexami
c acid vs 
Placebo 
Patients 
undergoi
ng 
cardiac 
surgery 
Composite 
of death 
and 
thrombotic 
complicati
ons 
(nonfatal 
MI, stroke, 
pulmonary 
“All other 
perioperativ
e clinical 
care will be 
according to 
standard 
practice as 
this is an 
effectivenes
ACEI/ARB
s, aspirin, 
clopidogre
l, statin, b-
blocker, 
diuretics, 
digoxin, 
NSAID, 
amiodaron
Periproc
edural & 
up to 7 
days 
 
- 1 
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embolism, 
renal 
failure, or 
bowel 
infarction) 
s trial and 
some 
elements of 
the trial are 
deliberately 
left to the 
clinicians’ 
discretion in 
order to 
reflect usual 
practice and 
maximise 
generalisabi
lity.  
Anaesthesia 
and surgery 
will be 
according to 
local 
practices…. 
All such 
relevant 
perioperativ
e data will 
be recorded 
on the CRF”  
e, and 
procedural 
characteri
stics 
2278241
7 
 
Acadesine 
vs Placebo 
Patients 
undergoi
ng 
cardiac 
surgery 
Composite 
of all-
cause 
mortality, 
nonfatal 
stroke, or 
need for 
mechanic
al support 
for severe 
left 
ventricular 
dysfunctio
n 
“Standard 
local 
procedures 
for CABG 
surgery or 
associated 
preoperative 
and 
postoperativ
e care were 
followed” 
(no 
protocol) 
ACEI/ARB
s, b-
blockers, 
statin, 
clopidogre
l, calcium 
channel 
blockers, 
nitrate, 
hypoglyce
mic 
medicatio
ns 
Periproc
edural & 
at 
discharg
e 
No 
informatio
n on 
procedural 
characteris
tics 
1 
2646066
0 
 
Methylpred
nisolone vs 
Placebo 
Patients 
undergoi
ng 
cardiac 
surgery 
Mortality 
and a 
composite 
of death 
and major 
morbidity 
(ie, 
myocardia
l injury, 
stroke, 
renal 
failure, or 
respiratory 
failure) 
No protocol 
available 
Procedura
l 
characteri
stics; 
periproced
ural 
medicatio
ns 
(inotropes, 
antifibrinol
ytic, non-
study 
steroids, 
ACEI/ARB
s, b-
blockers, 
antiplatele
ts, statins, 
vitamin K 
antagonist
s, PPIs, 
hypoglyce
mic 
Periproc
edural 
- 1 
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medicatio
ns) 
 
ACEI: angiotensive converting enzyme inhibitors, ACS: acute coronary syndrome, ARBs: Angiotensin II 
receptor blockers, CV: cardiovascular, FU: follow-up, GpIIb/IIa: Glycoprotein IIb/IIIa, HDL: high-densitiy 
cholesterol, HF: heart failure, LDL: low-density cholesterol, MACE: major adverse cardiac events, MI: 
myocardial infarction, NI: no information, NSAID: non-steroidal anti-inflammatory, PCI: percutaneous 
coronary angiography,  PPIs: Proton pump inhibitos, TIA: transient ischemic attack 
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Table S6. Reporting of co-interventions according to medication category (n=123). 
Drug Reported (%,n) Not adequately 
reported (%,n) 
Overall (n=123) 29.3 (36) 70.7 (87) 
Antihypertensives/diuretics/heart 
failure (n=14) 
14.3 (2) 85.7 (12) 
Antithrombotics/anticoagulants 
(n=45) 
35.6 (16) 64.4 (29) 
Lipid-lowering treatment (n=17) 23.5 (4) 76.5 (13) 
Antidiabetics (n=16) 56.3 (9) 43.7 (7) 
Antiinflammatory, antirheumatic 
medication (n=12) 
16.7 (2) 83.3 (10) 
Cardiac treatments & various 
(n=19) 
15.8 (3) 84.2 (16) 
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Table S7. Potential explanatory factors associated with the reporting of co-interventions (n=123). 
 Univariable analysis Multivariable analysis 
                                                                           OR 95%CI P-
value 
OR 95%CI P-
value 
Blinding of participants and/or 
personnel* 
(ref: Inadequate blinding) 
      
Adequate blinding 1.04 0.47 to 
2.27 
0.93 0.99 0.41 to 
2.38 
0.99 
Risk of bias due to deviations of 
intended interventions† 
(ref: “At risk of bias”‡) 
      
“At low risk of bias” 1.47 0.67 to 
3.21 
0.33 1.38 0.52 to 
3.69 
0.52 
Funding  
(ref: Industry) 
      
Non-Industry 2.06 0.86 to 
4.92 
0.10 2.24 0.80 to 
6.25 
0.12 
Trial design  
(ref: Non-inferiority) 
      
Superiority 0.63 0.26 to 
1.55 
0.32 0.38 0.13 to 
1.13 
0.08 
Follow-up 
(ref: >1 month) 
      
 <1 month 4.33 1.63 to 
11.52 
0.003 3.63 1.21 to 
10.91 
0.02 
*according to risk of bias due to lack of blinding of participants and/or personnel (RoB 1.0);†risk of bias due 
to deviations of the intended interventions: effect of adhering to treatment (RoB 2.0); ‡”at risk of bias”: “some 
concerns” and “at high risk of bias” 
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Table S8. Factors associated with balanced co-interventions among RCTs with adequate reporting of 
co-interventions (n=36). 
                                                           Univariable analysis 
                                                                           OR 95%CI 
Blinding of participants and/or personnel† 
(ref: Inadequate blinding) 
  
Adequate blinding* Omitted*  
Risk of bias due to deviations of intended interventions 
(ref: “At risk of bias”‡) 
  
“At low risk of bias” 6.33 0.63 to 63.63 
Funding  
(ref: Industry) 
  
Non-Industry* Omitted* 
 
Trial design  
(ref: Non-inferiority) 
  
Superiority 5.14 0.71 to 37.15 
Follow-up 
(ref: >1 month) 
  
 <1 month 2.19 0.22 to 22.19 
† according to risk of bias due to lack of blinding of participants and/or personnel (RoB 1.0) ; ‡risk of bias due 
to deviations of the intended interventions: effect of adhering to treatment (RoB 2.0);”at risk of bias”: “some 
concerns” and “at high risk of bias”;*All trials with unbalanced co-interventions were judged as inadequately 
blinded trials and were industry-funded. 
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Box S1. Detailed definition of procedural characteristics and periprocedural medications. 
  
- If the index procedure is cardiac surgery, minimum of procedural characteristics to be reported are: 
duration of aortic-cross clamping, on or off-pump surgery, duration of cardiac surgery. Minimum 
periprocedural medications to be reported are: antiplatelets, ACEIs/ARBs, statins, b-blockers (see ref. 29) 
- If the index procedure is percutaneous coronary angiography, minimum of procedural characteristics to 
be reported are: stents and type of stents (bare-metal stents, drug-eluting stents), balloon dilatation, 
arterial access site. –minimum of periprocedural medications to be reported are: Heparin or Bivalirubin, 
Aspirin, P2Y12 inhibitors drug use, Glycoprotein IIb/IIIa (see ref. 30) 
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Figure S1. Flow diagram of the systematic review (Study selection). 
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Additional records identified 
through hand search 
(n = 3) 
Records after duplicates removed 
(n = 1625) 
Records screened 
(n = 1625) 
Records excluded based 
on title and abstract 
(n = 1476) 
Full-text articles assessed 
for eligibility 
(n = 149) 
Full-text articles excluded, 
with reasons 
(n = 26) 
- Not RCTs n = 12 
- Other outcomes n = 13 
Other comparisons n = 1  
 
Studies included in 
qualitative synthesis  
(n = 123) 
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